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ABSTRACT
Cytochrome P450 2E1 (CYP2E1)-mediated hepatic and extra-hepatic toxicity is
of significant clinical importance. Diallyl sulfide (DAS) has been shown to prevent
xenobiotics such as alcohol- (ALC/ETH), acetaminophen- (APAP) induced toxicity and
disease (e.g. HIV-1) pathogenesis. DAS imparts its beneficial effect by inhibiting
CYP2E1-mediated metabolism of xenobiotics, especially at high concentration.
However, DAS also causes toxicity at relatively high dosages and with long exposure
times. The objective of the first project was to find potent DAS analogs which can
replace DAS as a research tool or as potential adjuvant therapy in CYP2E1-mediated
pathologies.
At first, we selected seven commercially available compounds that are similar to
DAS (DAS analogs) based on computational docking study. We performed ligandCYP2E1 docking study to determine the binding mode and binding energy. The analysis
suggested a relative potential for these DAS analogs as CYP2E1 inhibitor. We then
performed comprehensive inhibition kinetics of DAS analogs and determined the relative
IC50, Ki, and types of inhibition compared to that of DAS. The results showed that
compared to DAS, diallyl ether (DE) and allyl methyl sulfide (AMS) have lower Ki
values (3.1 and 4.4 μM, respectively vs. 6.3 μM for DAS) and IC50 values (6.3 and 11.4
μM, respectively vs 17.3 μM for DAS). However, thiophene (TP) showed similar
inhibitory capacities to that of DAS, and four other DAS analogs showed lower potency
than DAS. From this project, we found relatively more potent inhibitors of CYP2E1
which can potentially replace DAS.
Next, we investigated these analogs of DAS for their improved toxicity profiles
and their effectiveness in reducing ALC- and APAP-induced toxicity, and HIV-1
replication. In this project, we evaluated the toxicity and efficacy of these analogs using
hepatocytes, monocytes, and astrocytes where CYP2E1 plays an important role in
xenobiotic-mediated toxicity. Our results showed that thiophene, allyl methyl sulfide,
diallyl ether, and 2-prop-2-enoxyacetamide are significantly less cytotoxic than DAS in
these cells. Moreover, these analogs reduced ALC- and APAP-induced toxicity in
hepatocytes and HIV-1 replication in monocytes more effectively than DAS. Overall, our
findings are significant in terms of using these DAS analogs as a tool in vitro and in vivo,
especially to examine chronic xenobiotic-induced toxicity and disease pathogenesis that
occurs through the CYP2E1 pathway.
We also investigated the role of plasma exosomal CYP2E1 in mediating ALCand APAP-induced toxicity in hepatic and monocytic cells. Cellular CYP2E1 is wellknown to mediate ALC- and APAP-induced toxicity in hepatic and extra-hepatic cells.
Although exosomes have been gaining importance in understanding the mechanism of
intra- and inter-cellular communication, the functional role of drug metabolizing CYP
enzymes in human plasma exosomes are yet to be explored. We recently reported that
human plasma-derived exosomes contain substantial level of functional CYP2E1. In this
project, we investigated the potential role of plasma exosomal CYP2E1 in mediating
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ALC and APAP induced toxicity. We treated hepatic and extra-hepatic (monocytic) cells
with exosomes ± ALC/APAP. We observed that the plasma exosomes containing
CYP2E1 cargo further exacerbated ALC- and APAP-induced toxicity in both hepatic and
monocytic cells. Further, both exosomes- and ALC/APAP-induced toxicity was
reduced/abolished by CYP2E1 inhibitor, DE. However, only ALC-, but not exosomeinduced toxicity was reduced/abolished by CYP2E1 siRNA. These findings suggest that
ALC/APAP-induced toxicity in the presence of exosomes are mediated, at least in part,
by CYP2E1 enzyme. To validate these in vitro findings, we characterized plasma
exosomal contents in a binge-drinking animal model and their effect on ALC/APAPinduced toxicity in monocytic cells. Our results showed that ALC exposure caused a
significant induction of the plasma exosomal CYP2E1 level in a binge drinking murine
model. These exosomes containing increased levels of CYP2E1 caused significant
toxicity in monocytic cells compared to exosomes derived from control mice. Overall,
our results showed an important role of exosomal CYP2E1 in exacerbating ALC- and
APAP-induced toxicity. The study is significant in terms of understanding the role of
exosomal CYP2E1 in cell-cell interactions, and their effects on drug-induced toxicity.
In summary, we have identified several superior inhibitors of CYP2E1 which can
replace DAS as research tool and we have demonstrated for the first time that exosomal
CYP2E1 may contribute to ALC- and APAP-induced cytotoxicity.
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CHAPTER 1.

INTRODUCTION1

CYP2E1-mediated Metabolism and Toxicity
Human cytochrome P450 (CYP) enzymes are involved in the metabolism of 90%
of the drugs that are currently in use [1]. Among the 57 known functional CYP enzyme
families, CYPs 1, 2, and 3 participate in metabolic activation of the majority of foreign
substances [2]. Although the liver is the principal site of CYP-mediated metabolism,
many extra-hepatic tissues such as the blood, brain, and lungs express CYP enzymes in
different magnitudes and participate in drug clearance pathways [3-6]. CYP2E1 is one of
the key enzymes which participates in oxidizing low molecular weight substrates,
including alcohol (ALC/ETH) and acetaminophen (APAP), along with many
environmental pollutants and procarcinogens such as carbon tetrachloride [7-11] (CCl4).
CYP2E1 is virtually absent in fetal liver, however rapid expression occurs during the
postnatal period [12]. In adults, CYP2E1 represents approximately 7% of total CYP
expression [12]. Like all the major CYPs, CYP2E1 is primarily found in hepatocytes and
participates in the catalytic conversion of xenobiotics into a more polar form, thereby
facilitating their excretion or making them suitable substrates for phase II metabolic
enzymes [7]. Expression of CYP2E1 in many extra-hepatic regions such as the brain, gut,
kidneys, etc. has been reported in several disease conditions [2]. CYP2E1-mediated
production of reactive oxygen species (ROS), coupled with toxic metabolite formation,
has been suggested as one of the principal mechanisms of many inflammatory disorders
including liver injury [7]. Moreover, CYP2E1 is inducible by its own substrates [13] (e.g.
ALC) and also has been found to be upregulated in different pathological conditions [1416] (e.g. human immunodeficiency virus type-1 (HIV-1) infection, diabetes, obesity,
cancer, etc.). Moreover, the expression of this enzyme is highly regulated without the
presence of any substrate [17]. Therefore, the study of CYP2E1-mediated metabolism is
of great pharmacological and toxicological importance.
Epidemiology of ALC- and APAP-related disorders
ALC is one of the leading etiological factors for several crucial organ disorders
and acts as one of the causative factors for more than 200 diseases/injury worldwide [18,
19]. ALC is predominantly metabolized by the liver which is therefore the site of the
most damaging consequences of acute and chronic ALC consumption [8, 20]. Alcoholic
liver disease (ALD) is a major cause of cirrhosis, acute alcoholic hepatitis (AH),
hepatocellular carcinoma, etc. and thus contributes to significant mortality [21, 22].
However, other organs, which metabolizes ALC to certain extent, are also affected
adversely upon continuous use [23, 24]. According to the World Health Organization
(WHO), it is estimated that harmful use of ALC contributes to 5.3% (~3 million) of total
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annual deaths. Moreover, regular ALC consumption promotes disability and relatively
early death in comparison to non-drinking populations. Approximately 14% of total
deaths are attributed to ALC-associated disorders in the 20-39 year age group [18]. The
causal relationship between ALC drinking and many non-communicable diseases
including cancer has been well established [25], and ALC is also associated with several
serious infectious diseases such as tuberculosis and HIV/AIDS [26, 27].
APAP is a frequently used over the counter (OTC) analgesic in the USA and
worldwide [28, 29]. Annually, APAP is prescribed to around 6% of the US adult
population with a dose of more than 4 grams/day (recommended total dose is < 4
grams/day). The main reason behind the popularity of APAP as an analgesic is that,
unlike the other nonsteroidal anti-inflammatory drugs (NSAIDs), APAP does not cause
significant gastrointestinal toxicity [28]. Unfortunately, severe liver injury, including
liver failure culminating in death, can happen if ingested in high doses, either as a result
of acute overdose or chronic overuse [29]. APAP can cause significantly more damage in
combination with other drugs such as ALC [30]. In fact, the US Food and Drug
Administration (US-FDA) has taken numerous steps to raise public awareness with
regards to the concomitant use of ALC and APAP/APAP-containing drugs and their
potentially fatal impact on the liver [31]. Additionally, overuse of APAP has been
associated with disorders of organs other than the liver [32, 33]. However, the extrahepatic toxicity induced by APAP is less prevalent, and therefore, not extensively
reported.
Metabolism of ALC by CYP2E1
Although ALC possesses nutrient value (about 7 kcal/gram), it cannot be stored
like other nutrients such as carbohydrates (as glycogen) and fat (as triglycerides) [34]. In
fact, it remains mixed with body water until excreted. Moreover, there is negligible
hormonal control of ALC metabolism unlike other major nutrients. Hence, the major
burden to remove ALC from the body lies on the liver. Unsurprisingly, the enzymes
responsible for ALC metabolism are predominantly found in liver cells. There are four
enzymes that are involved in the metabolism of ALC: alcohol dehydrogenase (ADH),
aldehyde dehydrogenase (ALDH), CYP2E1, and catalase [24]. At lower ALC
concentrations, ADH converts ALC to acetaldehyde, which is further oxidized by ALDH
to acetate [35]. At elevated concentrations, CYP2E1, the principal CYP enzyme in the
microsomal ethanol oxidizing system (MEOS), plays a key role in ALC metabolism
which results in generation of reactive free radicals and toxic metabolites [20]. Catalase,
on the other hand, oxidizes ALC to acetaldehyde via a hydrogen peroxide (H2O2)dependent pathway in small quantities in the liver [34]. However, catalase along with
CYP2E1, is the primary ALC metabolizing-enzyme in the brain [23]. Due to its
electrophilic nature, acetaldehyde can bind covalently with DNA, lipids, and proteins
which can result in altered cellular homeostasis, conformational changes of proteins,
DNA damage and mutation, etc. [35].
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The MEOS comprises three CYP enzymes- CYP2E1, CYP1A2, and CYP3A4
[36]. However, being the predominant contributor to MEOS-mediated ALC metabolism,
CYP2E1 is of significant toxicological importance, especially in chronic and bingedrinking cases. At low concentrations, CYP2E1 may only account for the metabolism of
10% of total imbibed ALC [34]. The Michaelis-Menten constant (Km) of CYP2E1 for
ALC is about 10 mM (10 times higher than that of ADH), which suggests that with
increasing ALC concentration, as seen in binge/chronic drinking, the role of CYP2E1
becomes more substantial [34]. Moreover, since CYP2E1 is inducible by ALC, it
metabolizes a greater percentage of total ALC at higher concentrations. The mechanism
of CYP2E1 induction appears to be predominantly via a post-translational protein
stabilization pathway [37, 38]. This is not only true for liver CYP2E1, but also for the
extra-hepatic tissues such as kidney, brain, and intestine [39]. Another study has reported
that ethanol regulates oxidative stress-mediated CYP2E1 induction via protein kinase
C/c-Jun N-terminal kinase/specificity protein1 (PKC/JNK/SP1) pathway in monocytic
and astrocytic cell lines [40]. The increased CYP2E1-mediated ROS and acetaldehyde
production results in ALD as well as damage to extra-hepatic tissues.
There are a few CYP2E1 polymorphisms that have been identified, some of
which are associated with carcinogenicity by tobacco or other toxins [34]. However, none
of these polymorphisms have been linked with the frequency of ALD. The metabolism of
ALC in the brain is of particular interest since the exact mechanism of ALC-induced
toxicity in the central nervous system (CNS) is not very well characterized. Although
catalase has been found to be the principal ethanol-metabolizing enzyme in the brain,
growing evidence suggests that CYP2E1 plays a significant role in ALC oxidation to
acetaldehyde in the brain [23, 41]. It is interesting to note that acetaldehyde produced
outside the CNS is unable to cross the blood-brain barrier (BBB). Therefore, the levels of
acetaldehyde found in the CNS are most likely produced by in situ ethanol metabolism by
catalase and CYP2E1 [42-44]. However, chronic ALC exposure has been shown to
weaken the integrity of the BBB, which may facilitate external transfer of acetaldehyde
into the brain [45]. Recent discovery suggests that intercellular nanovesicles such as
exosomes can carry CYP2E1 from the bloodstream through the leaky BBB and
contribute to metabolism of ALC in the brain, thereby enhancing ALC-induced
neurodegeneration [46-48].
Metabolism of APAP by CYP2E1
CYP2E1 is responsible for metabolic activation of about 85 xenobiotics which
include hepatotoxic and carcinogenic agents [49]. At standard dose (less than 4 gm/day),
APAP is primarily converted to pharmacologically inactive glucuronide and sulfate
conjugates. A minor fraction (5-10%) of APAP is oxidized by CYP2E1 (to a lesser
degree, by CYP1A2 and CYP3A4) to a reactive metabolite, N-acetyl-p-benzoquinone
imine (NAPQI) [50]. NAPQI can bind with the cellular macromolecules such as
mitochondrial proteins and ion channels resulting in altered pathophysiology [51].
Normally, NAPQI is detoxified by hepatic glutathione load. However, following a toxic
dose, the conjugation pathways of APAP metabolism become saturated, resulting in
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enhanced oxidation by CYP2E1 to toxic NAPQI formation. Due to glutathione depletion
at high APAP doses, detoxification of NAPQI is reduced [50, 52, 53]. Increased binding
of NAPQI to hepatic proteins is considered to be the primary pathway of APAP-induced
hepatotoxicity [9].
APAP overdose surpasses all other etiological factors combined in mediating
acute liver failure in the western hemisphere [54]. Usage of CYP2E1 inhibitors such as
diallyl sulfide, chlormethiazole, disulfiram, etc. have been suggested as a possible
preventative therapy for APAP-induced liver injury [51, 55, 56]. However, their usage is
limited by either lower efficacy or potential toxicity [57]. Several xenobiotics such as
ALC and isoniazid are known CYP2E1 inducers [58, 59]. Regular co-administration of
these drugs with APAP can lead to enhanced NAPQI formation and severe glutathione
depletion which may lead to liver injury even at therapeutic APAP concentration [51].
APAP can readily cross the BBB and CYP2E1 in the brain can oxidize APAP to toxic
metabolite, NAPQI in situ. This can be particularly harmful for the CNS in the presence
of xenobiotics (e.g. ALC) which can induce CYP2E1.
Involvement of CYP2E1 in the Toxicity of Hepatic and Extra-hepatic Cells
CYP2E1 and hepatotoxicity
CYP2E1 is involved in metabolism of a wide spectrum of endogenous and
exogenous compounds. Just a few of the clinically relevant substrates of CYP2E1 are
ALC, APAP, isoniazid, salicylic acid, and CCl4 [60]. Due to remarkably high NADPH
oxidase activity, CYP2E1 is capable of producing increased reactive species such as
H2O2, hydroxyl radical, and superoxide anion resulting in oxidative stress [61, 62].
Oxidative stress is involved in many human diseases including cardiovascular disorders,
carcinogenesis, diabetes, Parkinson’s disease, heavy metal toxicity, radiation injury,
aging, drug-induced toxicity, etc. [61]. Among these, CYP2E1 plays a central role in
mediating liver toxicity induced by xenobiotics such as ALC, APAP, and CCl4,
predominantly via oxidative stress. The role of oxidative stress in ALC-induced liver
injury has been demonstrated convincingly in many studies [39, 60, 63-65]. ALC
exposure induces CYP2E1, which in turn oxidizes more ALC, generating further ROS
and enhancing lipid peroxidation. Use of CYP2E1 inhibitors and anti-oxidants have been
shown to reduce the severity of ALD in in vitro and in vivo studies, which further
confirms the role of CYP2E1-mediated oxidative stress in ALC-induced liver injury [6670].
CYP2E1 is also involved in non-alcoholic fatty liver disease (NAFLD), one of the
most prevalent chronic liver diseases in the United States [71]. CYP2E1 is not only
triggered by foreign xenobiotics but also by endogenous substrates such as
polyunsaturated fatty acids which can lead to ROS production and lipid peroxidation
[72]. Generally, NAFLD is considered as a comorbidity of obesity and metabolic
disorders such as diabetes in which cases CYP2E1 is also found to be significantly
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elevated [73-75]. The most severe form of NAFLD with inflammation is known as
nonalcoholic steatohepatitis (NASH). NASH is characterized by hepatomegaly, increased
serum aminotransferase levels, and similar histological manifestation as seen in AH [61].
Literatures suggest that CYP2E1 is crucially relevant in the development of NASH due to
its ability to induce oxidative stress, inflammatory responses, protein modifications, etc.
[76]. In human and rodent NAFLD/NASH models, increased level of CYP2E1 have been
found to be well correlated with the severity of liver damage [76].
Metabolism of xenobiotics such as APAP, CCl4, halothane, etc. may result in
severe liver injury depending on the extent of abuse. As mentioned earlier, CYP2E1mediated production of NAPQI is the principal mechanism of APAP-induced liver
damage. The definitive role of CYP2E1 in potentiating APAP-induced liver injury has
been demonstrated in many studies [56]. Similarly, it has been reported that reduction of
CYP2E1 expression in the liver prevents the early step of free radical generation by CCl4,
a well-known hepatotoxin [77]. CYP2E1-mediated metabolism of CCl4 in liver
microsomes results in the formation of reactive metabolites such as trichloromethyl
radical (CCl3•) which can react to membrane lipids and thus cause lipid peroxidation,
leading to altered cell structure and function in the liver. 1,2ǦDichloroethane (1,2ǦDCE),
otherwise known as ethylene dichloride, is a widely used organic solvent and chemical
intermediate that has been found to cause liver toxicity via CYP2E1-dependent metabolic
pathway [78]. Many other clinically used drugs such as cisplatin, chlorzoxazone,
isoniazid, sodium salicylate, phenobarbital, etc. have been reported to exert hepatotoxic
effect via CYP2E1 pathway [79].
CYP2E1 and toxicity in the extra-hepatic tissues
CYP2E1 and neurotoxicity
CYP2E1 is involved in several neurodegenerative processes, though the exact
mechanistic pathways have not been fully elucidated. In the alcoholic population, it is
suggested that CYP2E1 plays a critical role in neuroinflammation, most likely by
mediating oxidative damage to mitochondria and cellular proteins [80]. One study
showed that ADH- or CYP2E1-mediated metabolism of ALC in human primary neurons
produces ROS and nitric oxide (NO) via induction of NADPH/xanthine oxidase and
nitric oxide synthase pathway [81]. Increasing ROS and lipid peroxidation correlated
with reduced neuronal viability in this study. The same group reported that ALC-induced
oxidative stress can cause BBB dysfunction by multiple mechanisms. These mechanisms
include myosin light chain (MLC) kinase-mediated phosphorylation of MLC and tight
junction proteins, activation of inositol 1,4,5-triphosphate receptor-gated intracellular
release of Ca2+, and matrix metalloproteinases activation by tyrosine kinase [82-84].
Increased monocyte migration into the CNS occurs as a result of the dysfunctional BBB,
which promotes neuroinflammation [85]. Since oxidative stress acts as a precursor to
activation of these pathways, it is highly likely that CYP2E1-mediated oxidative stress in
ALC metabolism may be the underlying cause of BBB damage and neuroinflammation.
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Furthermore, polymorphism of CYP2E1 in certain populations have been implicated in
Parkinson’s disease in several studies [85-87].
CYP2E1 and cancer
CYP2E1 not only contributes to hepatic toxicity but also can play a role in cancer
progression. For example, CYP2E1-mediated mitochondrial oxidative stress and
endoplasmic reticulum stress can affect progression and metastasis of advanced breast
cancer [88]. Another report suggests that the induction of CYP2E1 and CYP1A1 can play
a potential role in pancreatic cancer pathogenesis [36]. Additionally, a CYP2E1
polymorphism has been associated with increasing risk of lung and colorectal cancer [89,
90]. CYP2E1-mediated ALC metabolism results in formation of reactive metabolites.
These metabolites can bind to cellular DNA and form carcinogenic exocyclic ethenoDNA-adducts [91]. Increasing evidence suggests significant role of CYP2E1 in chronic
ALC-induced carcinogenesis. CYP2E1 metabolizes various other procarcinogens present
in environmental pollutants and cigarette smoke to carcinogenic metabolites [91].
Moreover, several polymorphisms of CYP2E1 have been linked with chemically-induced
cancers in many studies [92].
Involvement of Oxidative Stress and CYP2E1 in HIV-1 Pathogenesis
It is well recognized that increased oxidative stress induces a plethora of
pathological conditions [93-95], and HIV-1 pathogenesis is no exception[96]. Even
without an external trigger, the HIV viral proteins such as the transactivator of
transcription (Tat) protein, the envelope glycoprotein gp120, etc. have been shown to
induce oxidative stress in people living with HIV-1/AIDS (PLWHA) [57, 97, 98]. The
persistent oxidative imbalance is due to the weakening of the host antioxidant defense
machinery, as manifested by reduced glutathione, catalase, superoxide dismutase (SOD),
and S-methyl transferase levels [57]. As a result of this reduced antioxidant capacity
along with increased inflammatory/immune responses, the human body suffers from
enhanced HIV pathogenesis as well as opportunistic infections such as tuberculosis (TB)
[99, 100]. It is important to note that there are approximately 14 million people living
with HIV-TB coinfection worldwide [101]. ALC drinking is another significant co-factor
that contributes to enhanced HIV-1 replication and toxicity of various vital organs such
as the liver and brain [102-104]. It is estimated that roughly 50% of the PLWHA are
regular consumer of ALC [57]. This not only affects adherence to anti-retroviral therapy
(ART), but also increases ART-induced hepatotoxicity, partially due to inefficient
metabolism of these drugs [105]. Furthermore, concurrent intake of ALC and analgesic
drugs such as APAP can lead severe glutathione depletion due to enhanced oxidative
stress which can exacerbate HIV-1-inducedimmune dysregulation [106].
Due to the advent of highly active ART medication, HIV/AIDS is no longer a
life-threatening condition. However, in chronic HIV-1 infection, delayed access and lack
of adherence to ART medication coupled with inability of these drugs to cross the BBB
can lead to HIV-associated neurocognitive disorders (HAND) in PLWHA [107, 108].

6

Especially, ALC abuse and HIV-1 infection in combination poses a major threat to
PLWH in this regard [109, 110]. The most severe form of HAND is known as HIV-1
associated dementia (HAD) [108, 111]. Although, the exact mechanism of HAD is not
clearly defined, oxidative stress has been identified as one of the key factors in this
condition [96, 112]. One study reported that, in the brains and cerebrospinal fluid (CSF)
of people with HAD, increased oxidative stress components were present [113].
Additionally, the use of antioxidants in ex vivo experiments resulted in reduced oxidative
stress associated toxicity. Another study reported that ALC abuse and HIV-1 infection
promoted oxidative stress and mitochondrial depolarization in primary human astrocytes
via a CYP2E1-dependent pathway [114], which contributes to increased cytotoxicity. In
many studies, ALC-induced overexpression of CYP2E1 leading to further ALC
metabolism and oxidative stress has been reported in hepatocytes, monocytes/
macrophages, and astrocytes [115-117]. Most importantly, similar results have been
observed in HIV-1 infection both in in vivo and in vitro systems [118, 119]. Taken
together, ALC-induced CYP2E1-mediated oxidative stress can lead to poor ART
metabolism due to hepatoxicity, which in turn can facilitate additional HIV-1 replication
resulting in neurocognitive disorders such as HAND and HAD.
From the reports discussed above, it is clear that CYP2E1 mediated metabolism
and resulting oxidative stress play a crucial role in xenobiotics- and disease-induced
toxicity. One of the fundamental corrective measures that has been proposed is to boost
the cellular antioxidant defense system, which can be done by using established
antioxidants or by inhibiting CYP2E1-dependent metabolic pathways. Unfortunately,
there are no safe and selective CYP2E1 inhibitors available to use in these
pathophysiological conditions. Also, the exact mechanistic pathway for CYP2E1mediated toxicity, especially in extra-hepatic regions, needs to be further investigated in
order to develop appropriate therapeutic regimens.
Potential of Diallyl Sulfide as a CYP2E1 Inhibitor
Diallyl sulfide (DAS, C6H10S) is a lipophilic thioether most commonly found in
garlic (Allium sativum). Consumption of garlic for its medicinal values has been practiced
for more than 3000 years. DAS is one of the principal organosulfur compounds present in
garlic imparting its anti-cancer, antioxidant, analgesic, and anti-inflammatory properties
[120]. When garlic is sliced or ground, the chief organosulfur compound, allin is
converted to allicin by the vacuolar enzyme alliinase. Allicin undergoes spontaneous
degradation and produces DAS (molecular weight: 114.2 g/mol) along with many other
oliferous compounds including diallyl disulfide (DADS) and diallyl trisulfide (DATS)
[121]. DADS and DATS have been reported to have beneficial effects in several studies
[122, 123], but DAS is the most extensively studied component of garlic due to its wide
range of therapeutic applications. Among the manifold activities of DAS, inhibition of
CYP2E1 enzyme has the most therapeutic potential and clinical relevance.
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Protective Effects of Diallyl Sulfide (DAS)
Anti-cancer effect
Oxidative stress can trigger profound alterations in cellular pathophysiology and
thus plays a critical role in numerous malignancies. Supply of an external antioxidant
agent therefore can be of great significance in oxidative stress-induced pathologies,
especially in chronic diseases. Several studies have shown that DAS treatment resulted in
significant upregulation of several antioxidant enzymes (AOEs) such as SOD, catalase,
glutathione reductase, etc. [124, 125]. Reduced glutathione (GSH) is an important free
radical/ROS scavenger, and its ratio with oxidized glutathione (GSSG), known as the
GSH:GSSG ratio, is considered as an indicator for oxidative stress [126]. In rats, DAS
treatment has shown enhanced GSH:GSSG ratio, indicating improved redox homeostasis
[125]. DAS-mediated upregulation of AOEs has been shown to be associated with the
transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway.
Anti-inflammatory effect
Anti-inflammatory properties of DAS have been reported in multiple studies. In
rat aortic smooth muscle cells, DAS reduced tumor necrosis factor (TNF)-α and
histamine-induced inflammatory responses [127]. DAS has also been found to modulate
the GSH redox cycle and inhibit the activation of nuclear factor kappa B (NF-ĸB) in
human T cells [121]. Moreover, in another study, it was observed that DAS reduced
bleomycin-induced activation of inducible nitric oxide synthase and the levels of
inflammatory cytokines, NF-ĸB, and interleukin- 1β in lung tissue [128]. Beneficial
effects by DAS were also observed in osteoarthritis patients, in whom DAS blocked
cyclooxygenase-2 upregulation by attenuating NF-ĸB activation [129].
Effect on drug metabolizing enzymes
Several organosulfur compounds in garlic have been found to induce phase I and
II drug metabolizing enzymes [120]. DAS treatment has been shown to selectively induce
CYP3A1/2 and CYP2B1/2 [130]. Moreover, increased activity of the phase II enzymes
UDP-glucuronosyltransferase, microsomal epoxide hydrolase, and glutathione-Stransferase were reported in DAS-treated rats compared to control animals [131].
However, the most significant interaction of DAS among the drug metabolizing enzymes
is with CYP2E1.
DAS as CYP2E1 Inhibitor
DAS has been studied for its inhibitory action on CYP2E1-mediated metabolism
of many toxic xenobiotics. Several studies strongly suggest its role as a CYP2E1 inhibitor
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and as a potential therapeutic or adjunctive therapy in CYP2E1-mediated pathologies.
The protective role of DAS as a CYP2E1 inhibitor in ALC-, and APAP-induced toxicity
as well as in HIV-1 comorbidity is discussed below.
Protection against ALC-induced toxicity
CYP2E1 dependent metabolism of ALC and resulting oxidative stress is one of
the principal etiological factors for hepatic and non-hepatic toxicity in chronic and binge
drinking populations. DAS, by inhibiting CYP2E1-mediated metabolism of ALC, has
shown protective effects in both in vitro and in vivo studies. For example, DAS treatment
partially protected primary human hepatocytes from ALC-induced cellular damage by
inhibiting CYP2E1 [132]. In another study, feeding rats with DAS reversed ALC-induced
changes in CYP2E1-dependent fatty acid metabolism and lipid peroxidation, which
resulted in improved liver function [133, 134]. Similarly, in chronic ethanol treated
human hepatoma cell line, DAS rescued the cells from CYP2E1-mediated oxidative
stress, toxicity, and aldehyde-protein adduct formation [135]. In a study conducted by the
Kumar group, it was observed that DAS pretreatment abolished ALC-induced ROS,
DNA damage, and cellular toxicity in monocytic and astrocytic cells [115]. A similar
effect was observed in ex vivo rat brains, where DAS pretreatment significantly reduced
acetaldehyde and acetate formation [136]. A recent study reported beneficial effects of
DAS in ALC-stimulated alcoholic cardiomyopathy. Taken together, it is likely that DAS
can be an effective tool in alleviating ALC-induced oxidative stress and organ damage.
Protection against APAP- and other drug-induced toxicity
Overdose of the popular analgesic, acetaminophen, is one of the leading causes of
acute liver injury in the world. A recent report showed that even a standard APAP dose
can be associated with liver failure [137]. It is well established that CYP2E1 plays the
key role in APAP-induced toxicity. Administration of DAS prior to or shortly before
APAP treatment significantly reduced liver injury in rat model [138]. In an in vitro study
using CYP2E1 transfected HepG2 cells, DAS showed cytoprotective effects by inhibiting
CYP2E1 mediated oxidation of APAP [139]. Another report demonstrated that DAS
lowered the synergistic toxicity caused by arachidonic acid and salicylate, which is an
anti-inflammatory and analgesic agent and a substrate of CYP2E1 [140]. These findings
suggest the ameliorating role of DAS as a CYP2E1 inhibitor in APAP- and other druginduced toxicity.
Protection from HIV-1 comorbidity
Drug abuse is very common phenomenon in PLWHA. Nearly half of the PLWHA
with HIV are regular alcohol drinkers. The HIV protein gp120 has been shown to be
associated with increased CYP2E1 expression which can worsen ALC-induced
hepatoxicity in this group. One study reported that CYP2E1 is involved in gp120 and
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methamphetamine (MA)-induced oxidative stress in astrocytes. DAS treatment
significantly reduced gp120/MA-induced ROS production and apoptotic cell death in
those cells [141].
Metabolism of DAS by CYP2E1 and Potential Toxicity
DAS is not only an inhibitor of CYP2E1, but metabolic conversion of DAS also
happens via the CYP2E1 pathway [142, 143]. The metabolites of DAS are diallyl
sulfoxide (DASO), diallyl sulfone (DASO2), and allyl mercaptan. The major two
metabolites DASO and DASO2 are formed by S-oxidation via CYP2E1, while allyl
mercaptan is a spontaneous breakdown product of DAS. These are further converted into
respective epoxides which are toxic to hepatic and extra-hepatic cells. Additionally, DAS
itself can undergo direct epoxidation which is also toxic. Further, the oxidation of DAS
causes autocatalytic destruction of the CYP2E1 enzyme. These phenomenon acts as a
roadblock for DAS to be considered for actual therapeutic use. Therefore, there is a
critical need for designing and developing novel DAS analogs which will retain the
CYP2E1 inhibitory characteristics of DAS but with reduced ability to act as a CYP2E1
substrate.
Despite showing protective effects in ALC-, APAP-, and other
xenobiotic/disease-induced toxicities by blocking CYP2E1-mediated metabolism, due to
its rapid metabolism by CYP2E1 to toxic metabolites, usage of DAS for chronic study
design or as a potential therapeutic modality is similarly limited. Figure 1-1 illustrates
this phenomenon.
Exosomes as Intercellular Mediators in Alcohol-induced Pathologies
According to the World Health Organization (WHO), alcohol-related
complications pose a major public health challenge to the world population, contributing
to approximately 5% of the global burden of disease and 6% of total deaths annually
[144]. Alcoholic liver injury, which includes hepatitis and cirrhosis, majorly contributes
to this problem. In addition to liver damage, excessive alcohol consumption can cause
severe damage to the central and peripheral nervous systems, the gastrointestinal tract,
the heart and vascular systems, and the endocrine and immune systems [145]. The WHO
reports that drinking alcohol is associated with more than 60 non-communicable diseases,
including cancer. Moreover, recent evidence points to a causative association between
alcohol intake and infectious diseases such as HIV-1, tuberculosis, and pneumonia [144].
For many years, investigators have undertaken research studies to understand these
alcohol-induced hepatic and extra-hepatic complications [146, 147]. However, the
molecular and cellular mechanisms of alcohol-induced toxic effects follow a multiplicity
of pathways. Despite tremendous advancements in the study of alcohol metabolism and
its effects, the complete mechanism(s) by which alcohol causes tissue injury, especially
extra-hepatic complications, are still poorly understood.
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Figure 1-1. General pathway of CYP2E1-mediated toxicity and potential benefit
and side effects of diallyl sulfide as a CYP2E1 inhibitor.
Modified with permission from Bentham Science Publishers. Rao P.S.*, Midde N.M.*,
Miller D.M., Chauhan S., Kumar A., Kumar S. Diallyl Sulfide: Potential Use in Novel
Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by
Targeting Cytochrome P450 2E1 (2015). Curr Drug Metab, 16(6), 486-503. (* Co-first
author). doi :10.2174/1389200216666150812123554.
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One potential phenomenon that is likely to play a role in alcohol-associated
pathologies, but has yet to be extensively studied, is the formation and release of
extracellular vesicles (EVs). EVs were first identified more than 50 years ago by two
different groups [148, 149]. At that time, they were referred as “platelet dust” or “procoagulant platelet-derived particles”. These vesicles, small membrane-bound microparticles containing proteins, RNA, and other biomolecules from their donor cell, have
only attracted mainstream scientific attention relatively recently. There are mainly three
distinct type of EVs- exosomes, microvesicles, and apoptotic bodies which are secreted
from eukaryotic cells [150]. These are categorized based on the size, mechanism of
biogenesis, and their biological contents. Exosomes are produced from multivesicular
bodies via endosomal pathway which includes internal budding and exocytosis [151].
Multivesicular bodies contain intraluminal vesicles which contains cellular proteins,
lipids, RNAs, etc. [152]. Inside cell cytoplasm, the intraluminal vesicles are formed by
components of the endosomal-sorting-complex-required-for-transport (ESCRT)
machinery, lipids, and tetraspanins (e.g. CD63, CD81, etc.). When the multivesicular
bodies dock and fuse with the plasma membrane, the intraluminal vesicles are released as
exosomes [152]. The size of exosomes typically varies from 30-150 nm. One the other
hand, microvesicles are generated as a result of outward budding off the plasma
membrane and the size ranges typically from 100-1000 nm. The biological contents of
microvesicles are quite similar to that of exosomes, mechanism of biogenesis being the
major distinction between these two EV types. Apoptotic bodies are largest among all the
EVs (size ranges from 1-5 μM) and are produced as a result of cell fragmentation/
blebbing during programmed cell death. Apoptotic bodies are sometimes referred as
apoptosomes [153]. In general, EVs have a short half-life (from a few minutes to ~ 6 h
after their release into the circulation), probably because of their subsequent uptake into
the recipient cells [152, 154]. In the current review, EV has been used as a generic term
which encompasses exosomes, microvesicles, and apoptosomes. However, it is important
to note that the role of exosomes has been discussed in more detail in the latter part of
this manuscript due to their greater clinical and biological implications.
Among all the EVs, exosomes in particular, has become a new buzzword in the
last decade, due to their relatively tightly regulated biogenesis and packaging processes.
Interestingly, when they first emerged on the scene in the late 1980s, exosomes were
thought to be the “garbage cans of the cell”, i.e. their function was assumed to be removal
of unnecessary proteins and other cellular debris [155]. Dr. Rose Johnstone from McGill
University, who was among the first to identify exosomes, believed that they could act as
key regulators in cellular processes, though exosomes research has gained significant
momentum only in the last decade [156, 157]. Due to advances in exosome isolation
techniques and proteomic analysis, emerging evidences have revealed that these oncecalled “dumpsters of cells” are crucial mediators of both cell-to-cell communication and
disease pathogenesis [155].
Recent findings show that EVs/exosomes can shuttle a plethora of key biological
agents such as microRNA (miRNA), mRNA, lipids, proteins, and other molecules
through biological fluids to both nearby recipient cells and those at distant sites [158,
159]. Due to the tightly regulated mechanisms of cargo sorting and process of vesicular

12

biogenesis, the cargo of EVs/exosomes generally varies between healthy and diseased
populations, suggesting a role for EVs/exosomes in mediating cellular communication
and disease progression [160]. EVs have been shown to play significant roles in the
innate immune response, tumor progression, angiogenesis, and other processes, and
recent data intriguingly suggest that alcohol can modulate the EV/exosomal pathway in
both hepatic and extra-hepatic tissue systems, potentially exacerbating these effects [161163]. This phenomenon can potentially help us to decipher the missing ‘pieces of the
puzzle’ of the broad spectrum of alcohol-induced toxic outcomes in various tissues. In
this review, we have attempted to summarize the latest discoveries relating to the effect
of alcohol on secretion of EVs, with a major focus on exosomes, specific packaging of
biomolecules and their transport via EVs/exosomes, and the potential impact of alcoholmodified EVs/exosomes on the recipient cells.
Alcohol-induced EVs/exosomes from Hepatic Cells in Cell-cell Communication
The liver is the principal organ responsible for the metabolism of most xenobiotic
compounds, including ethanol, often estimated to metabolize up to 90% of imbibed
ethanol [8]. It is equipped with high concentrations of the three major ethanolmetabolizing enzymes: alcohol dehydrogenases (ADHs), cytochrome P450 2E1
(CYP2E1), and catalase. Each of these enzymes metabolizes ethanol to acetaldehyde,
which causes DNA and protein adducts that greatly contribute to the risk of liver cancer
[164]. Additionally, the CYP2E1 enzyme, in the process of metabolizing ethanol to
acetaldehyde, produces superoxide anion and hydrogen peroxide. These reactive oxygen
species (ROS) are agents that have long been known to cause oxidative liver damage [8,
165]. These common metabolic pathways of ethanol are generally well understood. Even
so, alcohol still acts as a major risk factor in many disease conditions aside from the
widely heralded phenomenon of alcohol-induced liver injury. Since the ethanol molecule
displays tremendous biological reactivity, the consequences of alcohol abuse can be farreaching and complex. Therefore, alcohol-induced extra-hepatic complications remain a
major area of interest today. Recent studies strongly point to the potential involvement of
a defined group of biological nanovesicles, namely exosomes, as a key player in
modulating the deleterious effects of alcohol in different tissue systems. Cho et al. [166]
reported that exosomes obtained from mice with acetaminophen-induced liver injury can
cause hepatotoxicity in recipient naïve primary hepatocytes as well as in mice. Exosome
treatment caused elevation of plasma reactive oxygen species in mice and increased the
expression of proteins associated with apoptotic signaling pathway such as phosphoJNK/JNK, Bax, and cleaved caspase-3 in the recipient hepatocytes. Alcohol-induced liver
toxicity may follow a similar exosome–mediated communication pathway. In the
following section, we attempt to summarize the findings from the recent publications
regarding changes to liver-derived EVs/exosomes upon alcohol exposure and their
potential role in cellular communication, especially between hepatocytes and immune
cells such as monocytes.
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Hepatic EVs/exosomes in alcoholic hepatitis
Alcoholic hepatitis (AH) is one of the most devastating conditions associated with
heavy alcohol intake, manifesting as acute inflammation of the liver [167]. AH
pathogenesis follows a multifactorial pathway that involves intricate interplay between
metabolism of alcohol, liver damage, and inflammation. The identification and role of
different inflammatory mediators such as tumor necrosis factor α (TNFα) and interleukin1 β (IL-1β) in AH and gut microbiome-derived lipopolysaccharides (LPS) have been
studied extensively [168]. Damage to hepatocytes has been recently shown to be a
prerequisite of alcohol-induced liver inflammation [169]. However, many facets of this
pathogenesis remain unclear. For example, the exact mechanism of cross-talk between
hepatocytes and immune cells (such as monocytes, macrophages, T-cells, etc.) was
unknown until recently. Accumulating evidence suggests the potential role of exosomal
miRNAs in drug-induced liver, kidney, and muscle injury [170-173].
MiRNAs play a fundamental role in regulating AH pathogenesis. One recent
study reported that miR-122, miR-192, and miR-30a can act as useful diagnostic markers
for AH [174]. MiR-122 is abundantly expressed in hepatocytes, but to a much lower
degree in immune cells, and its function remains unclear. Momen-Heravi et al. [175]
observed that, after chronic and/or binge alcohol exposure, greater numbers of exosomes
that were rich in miR-122 were produced in human sera. They also demonstrated that
alcohol exposure increased miR-122-enriched exosome production in hepatocytes in a
dose-dependent manner. Most importantly, these exosomes horizontally transported miR122 to monocytes, which rendered them more sensitive to LPS stimulation, inhibited
heme oxygenase-1, and enhanced secretion of proinflammatory cytokines. Pre-treatment
with exosomes loaded with a miR-122 inhibitor prevented this proinflammatory
phenotype. In brief, this group demonstrated that exosomal transfer of miR-122 and
consequent immune modulation could potentially be an alternative pathway of immune
sensitization to LPS in AH pathogenesis. In addition, this study also demonstrates the
potential for use of exosomes as an effective vehicle for delivering gene and RNA
interference therapy in immune cells to reverse exosome-mediated deleterious effects
from alcohol-exposed hepatocytes.
Hepatic EVs/exosomes in alcoholic liver disease
Alcoholic liver disease (ALD) is an umbrella term for a broad spectrum of
disorders which includes AH, with or without cirrhosis, steatosis, hepatoccellular
carcinoma, etc. Due to the varying spectrum of ALD, the pathophysiology is
incompletely understood and hence, it is one of the leading causes of chronic liver
disease [176]. A recent study by Verma et al. [177] attempted to demonstrate the
mechanism by which macrophages are activated following alcohol exposure to
hepatocytes in alcoholic liver disease (ALD). The authors showed that ethanol treatment
significantly increased caspase-3 activation which triggered increased EV production in
hepatocytes. However, blocking of caspase-3 activation abolished the alcohol-induced
EV production, which indicates that alcohol triggers enhanced vesicle production via a
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caspase-dependent pathway. Moreover, they also showed that cluster of differentiation 40
ligand (CD40L), a member of the TNF superfamily, was highly packaged in exosomes
upon alcohol exposure (in vitro, in vivo, and ex vivo) and was associated with increased
inflammatory cytokine production as well as hepatic macrophage infiltration. Blocking of
CD40L reversed those phenomena, indicating that the crosstalk between hepatic and
immune cells upon ethanol exposure may occur through a CD40L-mediated pathway.
A similar study conducted by Saha et al. [178] showed that EVs isolated from
ALD mice had protein cargos distinct from the non-ALD mice, and that EV-induced
activation of macrophages was mediated by heat shock protein 90 (Hsp90). Hsp90 is a
molecular chaperone protein that has been previously shown to be involved in
macrophage activation by the anti-tumor agent Taxol and by bacterial LPS [179]. This
study demonstrated that upon intravenous administration of ALD-derived EVs into
alcohol-naïve mice, those EVs were uptaken by recipient hepatocytes and macrophages.
The EV-treated hepatocytes showed increased expression of monocyte chemoattractant
protein 1 (MCP1) compared to hepatocytes treated with control EVs. MCP1 is an
important chemokine that regulates recruitment of monocytes/macrophages in response
to inflammation [180]. Moreover, the authors observed significant induction of Hsp90 in
whole liver, and in purified hepatocytes isolated from ALD mice compared to pair-fed
mice. The authors hypothesized that this elevated amount of Hsp90 was highly likely to
be secreted via hepatic EVs into systemic circulation. Proteomic analysis showed that
ALD EVs did indeed have higher expression of Hsp90. Furthermore, treatment of
macrophages with recombinant Hsp90 resulted in a dose-dependent increase in the
expression of the pro-inflammatory cytokines TNF-α and IL-1β, whereas the level of
anti-inflammatory markers such as CD163 and CD206 were reduced. Inhibition of Hsp90
by a competitive inhibitor reversed this phenomenon, confirming the role of Hsp90 in
macrophage activation in ALD via an EV-mediated pathway.
Hepatic EVs/exosomes in fibrogenesis
In recent years, liver-derived exosomes have also been implicated in wound
healing mechanisms. For example, Nojima et al. [181] observed that in the case of
ischemia/reperfusion injury or partial hepatectomy, exosomes derived from primary
murine hepatocytes induced hepatocytic proliferation by fusing with recipient liver cells
and delivering neutral ceramidase and sphingosine kinase 2, resulting in increased
production of sphingosine-1-phosphate (S1P). S1P is a critical regulator in many
pathophysiological processes, including cell proliferation [182]. The number of exosomes
with proliferative effects increased after ischemia/reperfusion injury. In this scenario,
hepatic exosomes appeared to play a beneficial role in response to tissue injury. Though,
that is not true for all disease conditions. For example, exosomes may play an important
role in tissue fibrogenesis, which is a natural physiological response to stress-induced
tissue injury. However, several tissue repair processes are activated during stress
conditions, and chronic insults such as prolonged ethanol exposure lead to dysregulation
of the wound healing process, resulting in tissue fibrosis, scar formation, and ultimately
organ failure. Alcohol metabolism triggers the release of a major fibrogenic cytokine,
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transforming growth factor-beta-1 (TGF-β1), and hepatic stellate cell (HSC) activation,
which are key events in fibrosis progression [183]. These changes coincide with the
dysregulation of global miRNA expression in liver cells, which play crucial roles in HSC
functionality. Although the role of cellular miRNA-mediated HSC activation in alcoholic
fibrosis has been well studied, the potential contribution of exosomal miRNAs in this
phenomenon has not been delineated yet. In one recent study, Brandon-Warner et al.
[184] found that alteration of a single miRNA, miR-19b, can result in a change in the
expression and localization of multiple other miRNAs at the cellular and exosomal levels
in an alcohol-induced hepatic fibrogenesis model. MiR-19b is part of the miR-(17-92)
cluster family, and has been shown to be downregulated in activated HSCs. In addition,
alcohol increased the expression of pro-fibrotic genes and decreased miR-19b level in
HSCs. Interestingly, the level of miR-19b was significantly induced in plasma- and
activated HSC-derived exosomes. However, the clinical relevance of the release of
exosomal miR-19b in the fibrogenic pathway needs additional investigation.
Alcohol and EVs/exosomes Derived from Extra-hepatic Tissues in Cell-cell
Communication
Alcohol not only affects the liver, but also myriad other tissues. As mentioned
previously, numerous studies have focused on the effects of alcohol on hepatocytes and
liver-derived exosomes. However, very few studies exist concerning EVs/exosomes
derived from ethanol-treated non-hepatic cells and tissues. In the following section, we
summarize the findings of those studies that have been conducted on the effect of alcohol
on the secretion as well as content of EVs/exosomes derived drom extra-hepatice cells.
This information will contribute to our understanding of the role of alcohol in altering
EV/exosome-mediated intercellular communication, which in turn may lead to novel
therapies for alcohol-induced extra-hepatic toxicities.
Alcohol and EVs/exosomes in the immune system
Alcohol can increase release of EVs from immune cells such as monocytes [185].
Monocytes are differentiated into macrophages in response to various stimuls/signals.
These macorphages can polarize to either M1 (proinflammatory) or M2 (inflammatory)
phenotypes depending upon the type of stimulus/status of the disease. Saha et al. [185]
found that exosomal miRNA-27a plays a role in the process of macrophage
differentiation and/or polarization. Authors have demostrated that exosomes derived from
ethanol-treated monocytes stimulate naïve monocytes to differentiate into M2
macrophages, mediated through miR-27a (an M2-polarizing miRNA). The authors
validated these findings in vivo: circulating EVs in the plasma of alcoholic hepatitis
patients were found to have high expression of miR-27a [185]. Studying the transport of
miR-27a by exosomes derived from monocytes may give insights into the role of
exosomes in mediating the modulatory effects of ethanol on the mechanisms of
inflammation.
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Similarly, alcohol can also stimulate certain cells of the immune system to relase
cytokines [186] and these can be packaged in exosomes [187]. A recent publication from
our own laboratory investigating the plasma and exosomal cytokine levels in substance
abusers and HIV-infected subjects found that chronic alcohol comsumption could alter
the exosomal packaging of cytokines in vivo [187]. In particular, IL-10 is highly
packaged in the plasma exosomes of alcohol drinkers, though whether or not the higher
exosomal levels of this anti-inflammatory cytokine reflect a physiologically protective or
harmful phenomenon in chronic drinkers is a matter still under investigation.
Alcohol and EVs/exosomes in epithelia and endothelia
Ethanol also increases EV production in a dose-dependent manner from
endothelial cells derived from human umbilical vein (HUVECs) and dermal
microvasculature (HDMECs), according to a recent publication by Lamichhane et al.
[188]. Further, exposure of naïve endothelial cells to exosomes derived from ethanoltreated endothelial cells increases vascularization by down-regulating anti-angiogenic
miRNA-106b and up-regulating the pro-angiogenic long non-coding RNAs MALAT1
and HOTAIR [188].
Similarly, Atienzar-Aroca et al. [189] reported that retinal pigment epithelium
(RPE) cells also dose-dependently produced higher quantities of exosomes upon
exposure to ethanol. Further, these exosomes contained higher levels of vascular
endothelial growth factor receptor (VEGFR-1 and VEGFR-2) mRNA than control
exosomes. Interestingly, when exosomes derived from ethanol-treated RPEs and
untreated control cells were exposed to HUVECs, the progression of tube formation was
delayed by control exosomes and enhanced by ethanol-modified exosomes. Moreover,
the intracellular levels of VEGFR-1 and VEGFR-2 were also increased in recipient
HUVECs upon treatment with exosomes derived from the ethanol-exposed RPEs [189].
These findings indicate that EVs can be used as therapeutic targets for alcohol-induced
angiogenesis in pathological conditions.
Alcohol is a known risk factor of oral squamous cell carcinoma (OSCC). Recently
Momen-Heravi et al. [190] found altered miRNA expression in plasma EVs of patients
with OSCC compared to healthy patients, as well as higher total EV content. Further,
stimulation of an OSCC cell line with different doses of alcohol stimulated release of
EVs containing known oncogenic miRNAs, particularly miR-21. Treatment of
monocytes with EVs derived from OSCC cell lines transfered this miR-21, leading to
activation of the NF-kB pathway and stimulating production of MCP-1. These effects
were more pronounced with the administration of EVS from OSCC cells treated with
alcohol, further supporting the hypothesis that regular alcohol consumption may
exarcerbate oral cancer and provoke excessive inflammation.

17

Alcohol and EVs/exosomes in the heart
Cardiac myocytes are not particulalry secretory cells. However, they can release
exosomes upon exposure to certain stimulus or treatments [191]. Malik et al. [191]
observed that exosomes derived from ethanol-treated cardiac myocytes had different
protein content compared with exosomes derived from hypoxia/reoxygenationexperienced cells. Specifically, several proteins in ethanol-derived exosomes were found
to be mitochondrial in origin. Since mitochondrial dysfunction is known to play a major
role in oxidative stress, and heavy ethanol consumption contributes to cardiomyopathy
through oxidative stress [192], exosomes derived from alcohol-exposed cells are likely to
transport mitochondrial elements that could contribute to oxidative stress-induced
intercellular signaling. Also, as with other tissues mentioned previously, ethanol
increased exosome production from the cardiac myocytes via oxidative stress. Ethanol
exposure, variations in pH, low temperature (4°C), and hypoxia/reoxygenation conditions
did not alter the stability and membrane permeability of the myocytic exosomes [191]
suggesting that they retain their protein cargo under diverse physiological/pathological
conditions.
Alcohol and EVs/exosomes in the pancreas
Pancreatic stellate cells (PSC), upon exposure to ethanol, become activated and
release connective tissue growth factor (CCN2), which regulates collagen deposition and
fibrogenesis, in a dose-dependent manner. In a murine model of alcoholic chronic
pancreatitis, co-treatment of ethanol with the compound cerulein (an inducer of
pancreatitis) induced both CCN2 and miR-21 expression. Further, it was shown that, in
the activated PSCs, CCN2 not only increases collagen deposition but also induces miR21, which in turn increases CCN2 expression by a positive feedback mechanism [193].
The authors, Charrier et al. [194], have also demonstrated that exosomes derived from
PSCs package CCN2 mRNA and miR-21 proportionally to their relative cellular
expression, and that these exosomes are successfully delivered to recipient PSCs. The
exchange of RNA elements from one cell to another upon stimulation with ethanol
indicates that chronic drinking perhaps exacerbates existing pathological conditions such
as pancreatic fibrosis.
Plasma exosomes and cytochrome P450 enzymes
The presence and biological significance of drug metabolizing cytochrome P450
(CYP) enzymes in EVs especially in exosomes have not yet been investigated in detail.
In cases of chronic abuse, CYP2E1 plays a crucial role in mediating alcohol-induced
hepatic and extra-hepatic toxicity. A few recent studies, such as from Kumar’s group,
have shown that CYP2E1 is abundantly packaged in plasma exosomes in healthy and
alcoholic individuals, as well as in rodents [48, 195]. Cho et al. [195], demonstrated that
alcohol increased the total number of EVs and CYP2E1 expression in patients with
alcoholism and in an alcohol-fed animal model. Interestingly, increased EV production
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and vesicular secretion of several CYP isoforms appears to be modulated by cellular
CYP2E1, since these inductive effects were abolished in Cyp2e1-null mice and in the
presence of an enzymatic inhibitor, chlormethiazole. Moreover, CYP2E1 activity
increased oxidative and endoplasmic reticulum stress, contributing to further vesicular
packaging of CYP2E1. These EV-CYP2E1 could potentially act as a biomarker for liver
damage from long term alcohol exposure [195]. Kumar et al. [48] observed that the level
of CYP2E1 in exosomes derived from healthy human plasma was significantly higher
than other CYP isoforms such as CYPs 1B1, 2A6, and 3A4. Most importantly, the
exosomal CYP2E1 was metabolically active, which indicates its potential role in
contributing to ethanol metabolism and associated oxidative stress and toxicity in extrahepatic regions such as the brain. The major source of this exosomal CYP2E1 is likely to
be liver cells, since the levels of CYP2E1 mRNA in the plasma exosomes were reflective
of those of hepatocytes. In our own study, when plasma exosomes enriched in CYP2E1
were treated to naïve hepatocytes, they significantly increased alcohol- and
acetaminophen-induced toxicity, which were rescued by treatment with a selective
CYP2E1 inhibitor [unpublished observations]. This indicates that plasma exosomal
CYP2E1 has the potential to contribute to the pathophysiology in recipient cells. Further
investigation is ongoing to determine whether these exosomal CYPs, especially CYP2E1,
have any role in enhancing alcohol-induced comorbidities.
Potential Mechanisms of Alcohol-induced Toxicity via EVs/exosomes
Clearly, there is much that remains to be done to fill in the gaps in our current
understanding of how alcohol-modified EVs/exosomes may damage extra-hepatic
tissues. For example, as of yet, there are no research publications concerning the effects
of ethanol on the protein or RNA contents of EVs/exosomes derived from the cells of the
central nervous system. It is a mostly untapped area of study, and as such discussion of
pathogenic ethanol-induced exosomal content changes is necessarily speculative.
Nevertheless, there are some predictions that can be made with confidence, based upon
knowledge of overlapping interactions between ethanol exposure and EV/exosomal
secretion of established toxic proteins.
Cathepsin enzymes
Cathepsins are a family of lysosomal proteases that are highly expressed in many
cell types, especially phagocytes such as macrophages and microglia. Under stress
conditions, cathepsin enzymes (in particular cathepsins B and D) can be secreted into
extracellular space, where they can cause neurotoxicity through dysregulated proteolysis
[196]. For example, Amritaj et al. [197] demonstrated that the compound U18666A,
which is used as an agent for inhibiting cholesterol synthesis and transport in an in vitro
model of Niemann-Pick type C disease, induced expression and extracellular secretion of
cathepsin D from hippocampal neurons, which contributed to cell death in neurons and
fibroblasts. Fan and He [198] found that astrocytes expressing HIV Tat protein exocytose
their lysosomes, releasing cathepsin B and causing neuronal death.
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Both cathepsin B and cathepsin D have been investigated in Alzheimer’s disease
pathology, as they both are known to process amyloid precursor protein, the pro-peptide
of beta amyloid [199, 200] and have been observed to be induced in the brains of
Alzheimer’s disease rodent models [201, 202] and human patients [203]. There is some
evidence that these induced cathepsins may be neuroprotective in that they help to digest
beta amyloid plaques [204, 205]. However, CTSB inhibition has also been shown by
Hook et al. [206] to reduce beta amyloid and improve memory in a murine Alzheimer’s
model, indicating that it may also contribute to neurotoxicity. Regardless of this
conflicting data on their net effect, the general consensus in the literature is that
extracellular secretion of cathepsins increases in cases of Alzheimer’s disease [207] and
that secreted cathepsins directly cause neuronal apoptosis [197, 208, 209]. Ethanol has
been shown to enhance the expression and activity of both cathepsin enzymes in multiple
tissues, including the liver [210], pancreas [211], and brain [212]. The release of
cathepsin enzymes likely occurs through lysosomal leakage caused by ethanol-induced
oxidative stress, as high quantities of ROS can cause membrane instability of that
organelle in many cell types [213, 214]. Goetzl et al. [215] observed that cathepsin D was
packaged in neuron-derived exosomes secreted into plasma, and that the exosomal
expression of cathepsin D was greater in patients with severe Alzheimer’s disease. Kang
et al. [216] similarly observed increased expression of cathepsin D in exosomes derived
from retinal epithelia found in the aqueous humor of patients with macular degeneration.
Cathepsins B and D are also secreted in exosomes derived from macrophages in vitro,
both of which are dose-dependently induced with ethanol exposure [unpublished
observations]. With this in mind, there is good reason to expect that ethanol-induced
oxidative stress may induce exosomal secretion of active cathepsin enzymes, which may
contribute to long-lasting neurodegenerative conditions.
NADPH oxidase
Another potential protein of interest is the NADPH oxidase complex (NOX).
NOX is expressed in several cell types, particularly phagocytes, and when activated
produces large quantities of superoxide, contributing to oxidative stress [217]. The NOX
complex has been shown to be both activated and induced by ethanol exposure in
neurons, microglia, and macrophages both in vitro and in murine models of alcohol abuse
[218, 219]. Janiszewski et al. [220] were among the first to observe expression of NOX in
exosomes and microvesicles in plasma, which was pro-apoptotic when treated to
recipient endothelial and aortic smooth muscle cells. While it has never been studied, it is
likely that ethanol exposure may induce secretion of EV/exosomal NOX from
macrophages and microglia in excess, which could be a potent source of ROS-mediated
toxicity.
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Tau
Drinking alcohol is not definitively associated with disease severity or poorer
prognosis in Alzheimer’s disease [221], yet oxidative stress is known to have some
interaction with the pathways associated with its pathogenesis [222]. As ethanol
metabolism is a potent source of ROS there remains potential for alcohol to exacerbate
Alzheimer’s-associated pathologies. Indeed, it has been observed that ethanol can induce
phosphorylation of tau protein, the microtubule-associated protein whose dysfunction is a
hallmark of Alzheimer’s disease [223, 224]. Ethanol has also been shown by Gendron et
al. [225] to induce aggregation of tau in neuroblastoma cells in vitro, and inhibit its
clearance. Given that neurons can secrete tau in exosomes [226] and that microglia can
propagate the spread of tau through phagocytosis and re-exocytosis [227], it is likely that
chronic consumption of alcohol enhances the production and spread of phosphorylated
tau aggregates via exosomes, which may contribute to the progression of Alzheimer’s
disease.
MicroRNA-21
Alcohol has also been demonstrated to alter the miRNA transcriptome in many
tissues, inducing both protective and deleterious effects [228]. However, exosomal
transport of ethanol-induced miRNAs has only just begun to be investigated. In
particular, there is one miRNA that is known to be induced by ethanol exposure, to be
packaged into exosomes, and to have a complex role in the CNS: miR-21. It has long
been known that miR-21 has a role in regulating a number of genes, many of which are
associated with controlling cellular growth and proliferation. Under conditions of stress,
such as ethanol exposure, miR-21 can be induced, balancing tissue regeneration and
repair in the liver [229, 230]. It has also been shown to improve neurological outcomes
following traumatic brain injury in rats, indicating potential neuro-regenerative properties
as well [231]. However, as mentioned previously [190], these same qualities make miR21 a mediator of cancer in a number of different tissues, as it protects tumor cells by
modulating inflammation and apoptosis [232]. It has been observed to be secreted in
exosomes in a murine glioblastoma model and elevated in exosomes derived from the
serum and spinal fluid of patients with high-grade glioma [233, 234]. In addition to being
pro-cancerous, one study by Yelamanchili et al. [235] showed that miR-21 in
extracellular vesicles could also be directly neurotoxic through interactions with TLR7.
With the knowledge that miR-21 can be induced by alcohol, and given its associations
with neurotoxicity and cancer, the scientific community would be well served by greater
understanding of the role of exosomal transport of miR-21, and other potentially harmful
miRNA that may be induced by ethanol, in these conditions.
HIV elements
Alcohol consumption is also known to enhance HIV pathogenesis [236-238]. It is
very well established that oxidative stress can induce viral replication and the expression
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of viral proteins, by multiple mechanisms [239, 240]. Ethanol metabolism, a significant
source of oxidative stress, therefore, also unsurprisingly enhances viral replication in Tcells and mononuclear cells [236, 241]. This phenomenon also occurs throughout the
CNS [242] and consequently alcohol drinking is considered a risk factor for the
development of HIV-associated neurocognitive disorders [109, 243]. Aside from
inducing viral replication, ethanol also interferes with the metabolism of some
antiretroviral drugs, further worsening disease progression in infected alcohol drinkers
[244, 245]. Additionally, ethanol exposure has been shown to potentiate the neurotoxic
effects of HIV proteins such as gp120 and Tat, through sensitization of the N-methyl Daspartate receptor, leading to excitotoxic cell death [246, 247].
HIV, like some other viruses, is known to utilize exosome processing and
secretion machinery (such as the ESCRT complex) to facilitate its own reproduction
[248]. As a consequence of that, viral proteins and RNA are packaged and secreted in
exosomes and other extracellular vesicles, even in the presence of antiretroviral therapy
[249] These viral elements, such as the proteins Tat and Nef, have been shown to have a
variety of pathogenic effects [250-252].Taken together, it is highly likely that the
exosomal transport of HIV components is enhanced by ethanol exposure through
oxidative stress-induced transcription of the viral genome, leading to increased
susceptibility to intercellular viral infection, inflammation, direct neurotoxicity, and other
deleterious conditions associated with HIV infection. However, this phenomenon, like
the other previously suggested mechanisms of ethanol-induced toxicity mediated by
exosomes, has not yet been demonstrated experimentally, and is merely speculative given
the available data. This is an area in great need of additional research, as alcohol abuse
and its effects on neurodegeneration are still not yet fully understood but continue to
affect millions of people worldwide. Figure 1-2 provides a summarized illustration of the
above discourse.
Discussion
Alcohol alters the miRNA and protein content (e.g. miR-27a, miR-122, CD40L)
of EVs such as exosomes from multiple tissues, having complex immunomodulatory
effects. EV/exosomal RNA (miR-21, miR-19b, VEGF mRNA) and proteins (HSP90,
CCN2) can be potentially involved in alcohol-induced exacerbation of existing disease
conditions, such as pancreatic fibrosis, cardiomyopathy, and some cancers. We also
considered some potential EV/exosomal agents that may contribute to alcohol-induced
damage in other tissues, such as the central nervous system (NOX, cathepsin enzymes),
as well as exosomal elements associated with other conditions that may be enhanced by
alcohol exposure (phosphorylated tau and HIV protein and RNA elements). In
conclusion, recent investigations, limited though they are, point to a consensus that
exosomes derived from alcohol-exposed cells, irrespective of origins, can play a crucial
role in disease progression by modulating biological pathways via delivery of cargo to
recipient cells. This is an exciting area of research which is in need of further
investigation.
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Figure 1-2. Potential EV/exosomal mechanisms of alcohol-induced toxicity.
In response to ethanol exposure, exosomal transport of pathogenic elements to nearby or
distant cells can act as cellular messenger system which may facilitate/enhance disease
progression in cancer, HIV, liver disease, neurodegenerative disorders, etc.
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EVs/exosome are not just buzzword in the scientific community anymore. As a
result of advances in large-scale proteomic analysis since the early 2000s, research in this
area has taken a major leap forward in recent years. However, we are still in the nascent
phase of the EV/exosome revolution. In other words, extensive investigation is essential
to establish a complete understanding of the role of EVs/exosomes in disease
progression, particularly in the context of concurrent xenobiotic exposures. For example,
the impact of alcohol on EV contents in alcohol-related co-morbidities is an understudied area, despite its widespread use and well-established role in exacerbating many
pathological conditions. Due to limited literature availability and the lack of well-defined
target pathways of alcohol-associated co-morbidities, it is apparent that there is a critical
need to find biomarkers for alcohol-induced toxicity outside of the liver. Recent reports
suggest EVs/exosomes can play a crucial role in finding these desired biomarkers [253].
The circulation of EVs/exosomes throughout the body via body fluids, particularly
plasma, urine, and saliva, make them appealing, because of their convenient accessibility
for sample collection, sometimes referred to as “liquid biopsy” [254]. There have been
several studies identifying EVs with specific contents as biomarkers for various
conditions, especially cancers [255]. The ability of EVs/exosomes to migrate from their
tissues of origin into wider circulation through plasma also allows for diagnosis of
disease in otherwise less accessible regions of the body, such as the CNS. For example,
neuronally-derived exosomes collected from plasma have been found to carry markers
for Alzheimer’s disease in Alzheimer’s patients, as well as in individuals with Down
syndrome [215, 256]. It is highly likely that circulating exosomes contain specific
markers for alcohol-induced toxicity outside of the liver, which would provide a novel
and non-invasive way of diagnosing specific morbidities in chronic alcohol drinkers that
require therapeutic intervention. As discussed in this review, in a murine chronic
pancreatitis model, exosomes appear to play a crucial role in pancreatic fibrogenesis, a
pathological outcome that is enhanced by chronic alcohol exposure [194]. Identification
of pancreatic exosomes containing high levels of the fibrogenic elements CCN2 and miR21 in the plasma of chronic drinkers could allow for earlier diagnosis and therapy to
counteract alcohol-enhanced pancreatitis and fibrosis. Considering that miR-21 is also
induced in the liver during alcohol metabolism, and is furthermore a known oncogenic
agent, miR-21 and other EV/exosomal ethanol-induced miRNAs may be valuable early
indicators of alcohol-associated cancers [229, 230, 232-234, 257]. Table 1-1 contains the
list of pathogenic elements that are involved in ALC-induced disease pathogenesis.
Based on the literature reports, it is evident that alcohol-induced changes in
cellular contents are also coincided with the changes in their EV/exosomal cargos.
Alcohol exposure modifies the contents of both hepatic and extra-hepatic EVs which are
translocated to other naïve liver cells or non-hepatic cells. This intercellular transfer of
biomolecules results in increased/decreased inflammatory responses in the recipient cells.
EVs, especially exosomes represent the next frontier in the areas of diagnosis and therapy
of a plethora of pathological conditions, many of which are enhanced or altered by
concurrent substance abuse. It is vital for patient care that the role of EVs/exosomes in
these conditions, and how that role changes in cases of chronic drug use, is elucidated.
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Table 1-1. Pathogenic exosomal elements in response to alcohol exposure.
Donor cells
Hepatocytes

Recipient cells
Monocytes

Mediators
miR-122

Hepatocytes

Macrophages

CD40L

Hepatocytes

Hepatocytes,
monocytes

Hsp90

Hepatocytes

Hepatocytes

Hepatic stellate
cells
Monocytes

Hepatic stellate
cells
Monocytes

Ceramidase and
sphingosine
kinase- 2
miR-19b

Endothelial cells

Endothelial cells

Retinal pigment
epithelium cells
Oral squamous
cell carcinoma

Endothelial cells
Monocytes

MALAT1 and
HOTAIR
VEGFR-1 and
VEGFR-2
miR-21

Pancreatic stellate
cells

Pancreatic stellate
cells

CCN2 and
miR-21

mi-R27a
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Implications
Immune
sensitization in
AH
Macrophage
activation in ALD
Macrophage
activation in ALD
mice
Fibrogenesis

References
[175]

Increased hepatic
fibrogenesis
Differentiation to
M2 macrophages
CD34-mediated
vascularization
Vascularization

[184]

NF-kB activation
and MCP-1
secretion
Collagen
production and
fibrogenesis

[190]

[177]
[178]
[181]

[185]
[188]
[189]

[194]

A more complete understanding of the interplay between EVs/exosomes and alcohol will
allow for greater degrees of personalized care for the individuals who consume it or other
commonly used substances such as tobacco constituents, cannabinoids, and opioids,
ultimately leading to superior public health outcomes.
Based on the scientific discourse above, we undertook two unique projects to 1)
identify a superior alternative to DAS as a CYP2E1 inhibitor which can be used in
chronic mechanistic studies related to CYP2E1 mediated toxicity and 2) to investigate the
potential role of exosomal CYP2E1 in mediating xenobiotic-induced toxicity. The
principal component of these two projects is xenobiotic- and diseases-induced CYP2E1associated toxicity.
Project 1
Scientific premise
The scientific premise of the first project is based on the literature reports: 1)
CYP2E1 is involved in metabolic activation of several clinically important xenobiotics
such as alcohol, acetaminophen, etc. [1, 40, 56, 79, 258]; 2) CYP2E1 is induced by its
own substrates and hence, can cause further oxidative stress and acetaldehyde production
which can lead to severe hepatic and extra-hepatic toxicity [259-261]; 3) Diallyl sulfide
(DAS) is a selective inhibitor of CYP2E1 and has been shown to have protective effects
in xenobiotics- and diseased-induced toxicity in many in vitro and in vivo studies [120];
4) DAS is also a substrate of CYP2E1, and its metabolism by CYP2E1 produces toxic
sulfur-containing metabolites [120]; 5) Due to its own toxicity at relatively high
concentrations and in cases of chronic use, the usage of DAS is limited mainly to acute
study; 6) Molecular docking study has been identified as a tool for the identification of
potentially novel compounds as enzyme inhibitors [262-265].
Hypothesis
Based on these scientific premises, we hypothesize that structural modification
with the aid of molecular modeling improves the efficacy and safety profile of novel
DAS analogs. The new analogs are less cytotoxic than DAS at high concentrations and
upon chronic exposure and are capable of reducing CYP2E1-mediated toxicity in hepatic
and extra-hepatic cells especially in alcohol and acetaminophen abuse.
Objective and aims
The objective of the project is to identify relatively safer and more potent DAS
analogs which can be used, at least, as a suitable research tool in CYP2E1-related study
design under chronic condition.
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Aim 1: Kinetic characterization of DAS analogs for their novel role as
CYP2E1 inhibitors
x
x
x

Molecular docking assay
CYP2E1 inhibition assay
CYP2E1 kinetic data analysis

Aim 2: Evaluation of structural analogs of DAS as novel CYP2E1 inhibitors
for their protective effect against xenobiotic-induced toxicity and HIV
replication
x
x
x
x
x
x
x
x

Cell culture (hepatic, monocytic, and astrocytic cell lines) and treatment
CYP2E1 activity in U937 monocytic and SVGA astrocytic cells
Measurement of reactive oxygen species and cell viability using flow cytometry
XTT cell viability assay
LDH activity assay
Caspase 3 activity assay
HIV p24 ELISA
Statistical analysis
Project 2

Scientific premise
The scientific premise of this project is based on the available literature reports: 1)
Exosomes, cellular nanovesicles (<150 nm), are secreted by almost all cell types into
their extra-cellular environment and biofluids such as plasma; 2) The semi-selective
ability of exosomes to package and transport diverse biological cargos such as proteins,
mRNA, miRNA, and small molecules allow them to serve both as diagnostic biomarkers
of disease states and as potential therapeutic targets [175, 266]; 3) Exosomal transport
between cells via plasma can be either beneficial or deleterious [267-269]; 4) It has been
recently reported that a relatively large amount of functional CYP2E1 is present in
human plasma exosomes compared to other CYP enzymes [48]; 5) Study has also shown
that the relative levels of CYP2E1 mRNA and protein in plasma exosomes are higher
than those of monocytic cells and exosomes derived from hepatic and monocytic cells
[48]; 6) Upon exposure to naïve cells, exosomal content have been shown to alter the
pathophysiology of the recipient cells [166]; 7) Although, CYP2E1 mediated hepatic
toxicity is well characterized, the mechanism of extra-hepatic toxicity by CYP2E1
mediated xenobiotic (e.g. alcohol, acetaminophen, etc.) metabolism is not fully
understood [40, 270].
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Hypothesis
Based on these scientific premises, we hypothesize that plasma exosomes
contribute to alcohol- and acetaminophen-induced toxicity by delivering its CYP2E1
cargo into the naïve recipient cells.
Objective and aim
The objective of the project is to evaluate the role of plasma exosomal CYP2E1 in
exacerbating alcohol- and acetaminophen-induced toxicity in hepatic and extra-hepatic
cells.
Aim: Investigation of the role of plasma exosomal CYP2E1 in alcohol- and
acetaminophen-induced toxicity
x
x
x
x
x
x
x
x

Cell culture and treatment
Isolation and validation of exosomes from human and mouse plasma
Acetylcholine esterase assay
Exosomes labeling and uptake
CYP2E1 SiRNA transfection and treatment
Western blot
LDH cell viability assay
Statistical analysis

28

CHAPTER 2. KINETIC CHARACTERIZATIONS OF DIALLYL SULFIDE
ANALOGS FOR THEIR NOVEL ROLE AS CYP2E1 ENZYME INHIBITORS2
Introduction
Diallyl sulfide (DAS), a thioether present in garlic extract, has garnered
significant attention from scientific communities since the early 1990s. Researchers have
explored the use of DAS for its multifarious applications that includes anti-cancer, antioxidant, and anti-inflammatory properties [120]. DAS has been used most frequently in
the prevention against toxicities induced by xenobiotics such as alcohol and
acetaminophen by selectively inhibiting cytochrome P450 2E1 (CYP2E1) [120].
CYP2E1 is involved in the metabolism of more than 85 xenobiotics [92]. CYP2E1mediated metabolism produces reactive oxygen species (ROS) and toxic metabolites,
which causes cytotoxicity. For example, CYP2E1 metabolism of acetaminophen (APAP)
causes production of a toxic metabolite N-acetyl-p-benzoquinone imine, and APAPinduced liver injury accounts for more than half of overdose-related liver failure in the
United States [271]. In addition, ethanol is known to induce CYP2E1, which
subsequently metabolizes ethanol and causes ROS and acetaldehyde mediated cellular
toxicity and cancer of hepatic and non-hepatic organs/systems [39, 272]. DAS, through
CYP2E1 inhibition, has shown protective effects against ethanol- and APAP-mediated
hepatoxicities in several studies [273-275]. DAS has also been extensively used both in
vitro and in vivo study as a tool to inhibit CYP2E1 in hepatic as well as a number of
extra-hepatic cells [276].
However, despite DAS being a selective inhibitor of CYP2E1, it has failed to
achieve clinical relevance as a drug, as well as, its application in chronic in vitro/vivo
study as a tool due to its own potential toxicity. At a relatively high concentration and
chronic exposure, DAS is toxic to hepatic and extra-hepatic cells [120]. In addition,
although DAS is being used as a tool to inhibit CYP2E1, it is poorly characterized with
regards to CYP2E1 inhibition. Our major goal is to find a superior alternative to DAS,
which overcomes the limitations of DAS, and can be used as a better research tool to
inhibit CYP2E1 in various pathological conditions. Furthermore, novel DAS analogs
have the potential to be used as adjuvant therapy in various pathological conditions. In
this study, we selected seven commercially available compounds, which resembles DAS
structure. These compounds were characterized for binding affinity using ligand-docking
analysis followed by CYP2E1 inhibition study.

2
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Materials and Methods
Chemicals
Diallyl sulfide (DAS), allyl methyl sulfide (AMS), allyl ethyl sulfide (AES),
diallyl ether (DE), thiophene (TP), 2-(prop-2-en-1-yloxy) ethan-1-amine (PEA), and 5hexen-1-amine (5,1 HA) were purchased from Sigma-Aldrich (St. Louis, MO). 2-prop-2enoxyacetamide (PEXA) was purchased from Aldlab Chemicals (Woburn, MA). The
stock solutions for these compounds were prepared in acetonitrile that was bought from
Sigma.
Molecular docking study
Molecular modeling studies were performed using the Schrodinger Molecular
Modeling Suite 2015 (Schrödinger, LLC, NY) as described [277, 278]. The initial models
of human CYP2E1 for docking were taken from the Protein Data Bank. Among the six
X-ray crystal structures available for human CYP2E1, we chose the 3KOH for docking
DAS and all the analogs based on completeness, resolution, and ligand binding pose
[279]. Protein and grid preparations were performed using the Protein Preparation Wizard
with default protocol, and the grid of the CYP2E1 active site containing heme iron was
defined. All compounds were prepared using the Ligprep module, before they were
docked into the active site with metal constraints using the Glide module in the software.
CYP2E1 inhibition assay
The inhibition of CYP2E1 activity by DAS or its analogs was measured using
standard para-nitrophenol (p-NP) hydroxylation assay as described before [280]. Briefly,
the final reaction mixture contained 50 mM potassium phosphate buffer (pH 7.4), 2
pmol/μL of CYP2E1 baculosomes (Thermo Fisher Scientific, Waltham, MA), and
varying concentration of p-NP (5, 15, 30, 50, and 100 μM) and inhibitors (5, 10, 25, 50,
100, and 200 μM). Upon pre-incubation at 37°C for 5 minutes, the reaction was initiated
by adding 26 mM NADPH and carried out for an hour at 37°C. Upon terminating the
reaction by 20% (w/v) trichloroacetic acid, the reaction was neutralized by 2M NaOH
and absorbance was measured at 535 nm using a micro plate reader (Cytation™ 5 Cell
Imaging Multi-Mode Reader, BioTek, VT). The absorbance without an inhibitor was
normalized to 100% activity of CYP2E1.
CYP2E1 kinetic data analysis
The CYP2E1 inhibition kinetics were analyzed using GraphPad Prism 5 software
(GraphPad Software Inc., San Diego, CA). The half maximal inhibitory concentration
(IC50) was determined by fitting curve to data by non-linear regression. The Michaelis-
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Menten constant (Km) and maximal reaction velocity (Vmax) were obtained by using the
Michaelis–Menten non-linear regression equation. The experimental data were reanalyzed with the appropriate equation to determine the inhibition type and inhibition
constant (Ki). Goodness-of-fit criteria were used to define the inhibition pattern.
Results and Discussion
Docking study of the analogs with CYP2E1 active site
To find a superior DAS alternative, we performed a structure activity study. The
central sulfur atom in DAS structure interacts with the heme of CYP2E1 active site,
thereby acting as an inhibitor. However, DAS is also metabolized at the same position
resulting in production of toxic sulfur metabolites such as diallyl sulfoxide and diallyl
sulfone [120]. We analyzed seven compounds (AMS, AES, DE, TP, PEA, 5,1 HA, and
PEXA) that resemble DAS, but have slightly different chemical moieties (Figure 2-1A).
We chose analogs that altered DAS at the central hetero atom by replacing sulfur with
oxygen (DE, PEA, and PEXA), or by completely removing sulfur (5,1 HA). These
alterations should result in DAS analogs retaining their ability to interact with the heme
of CYP2E1 active site but losing their ability to be oxidized into toxic metabolites. We
also chose DAS analogs that had stronger nucleophiles at the carbon atom adjacent to the
hetero atom (PEA, PEXA, and 5,1 HA) to increase the binding strength of the analogs to
the active site. Furthermore, we chose compounds with smaller side chain (AES and
AMS), which is likely to improve the binding affinity as well [120]. Low molecular
monocyclic aromatic compounds are also a viable option as the binding site of CYP2E1
(Figure 2-1B) exists within a narrow channel, unlike other CYP active sites [281].
Therefore, we chose a cyclic analog of DAS (TP), which is likely to strengthen the
binding as an inhibitor.
To determine the potential binding mode and molecular interactions between the
analogs and CYP2E1 at the active site, we performed a docking study. All the
compounds generally showed similar binding mode, in that they occupied approximately
the same space surrounded by a group of hydrophobic residues and the “necklace” of
phenylalanine side chains including Phe298, Phe116, and Phe207, above the heme
(Figure 2-1B). In each structure, the heteroatom (oxygen or sulfur) interacts with the
heme iron with distances of 3.15 - 3.58 Հ, whereas the alkyl chain or aromatic ring
extends towards the helix I. Among all the compounds, TP favors a S-S interaction with
the phenylalanine side and shows the best docking score of -4.86 (Table 2-1). However,
unlike the thiophene ring, the alkyl chains in the other compounds are flexible and lack a
S-S interaction with the surrounding residues. Therefore, the study predicts that
introducing aromatic moieties would increase interactions with CYP2E1. We also
observed a higher docking score for AMS (-3.24) than DAS (-1.56). These results are
consistent with our hypothesis.
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Figure 2-1. Structure of the analogs and docking with the CYP2E1 crystal
structure.
A) The structures of the seven commercially available DAS analogs that were used for
this study. B) Docking of DAS and analogs with human CYP2E1 crystal structures using
Schrödinger Molecular Modeling Suite 2015. All the compounds were prepared using the
Ligprep module, and then docked into the active site with metal constraints. The results
showed similar binding mode for all DAS analogs
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Table 2-1.

Summary of the CYP2E1 inhibition kinetics of the analogs.

Analogs

Inhibition type

Ki (μM)

IC50 (μM)

Diallyl sulfide
(DAS)
Allyl methyl
sulfide (AMS)
Thiophene (TP)

Competitive

6.3 ± 1.0

Competitive

Diallyl ether
(DE)
5-hexen-1-amine
(5, 1 HA)
2-(prop-2-en-1yloxy) ethan-1amine (PEA)
2-prop-2enoxyacetamide
(PEXA)

17.3 ± 1.1

Maximal
inhibition (%)
97

Docking
score
-1.54

4.4 ± 0.9

11.4 ± 1.1*

100

-3.25

Competitive

7.7 ± 1.2

19.4 ± 1.1

98

-4.86

Competitive

3.1 ± 0.2*

6.3 ± 1.2*

100

-0.17

Uncompetitive
Non-competitive

~7.3 (ambiguous)
~10.5 (ambiguous)

74.7 ± 1.2*

75

-1.88

Uncompetitive
Non-competitive

19.3 ± 2.3*
34.1 ± 3.3*

43.7 ± 1.4*

71

-1.27

Uncompetitive
Non-competitive

246 ± 47*
363 ± 64*

91.4 ± 1.6*

20

-1.73
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Docking score does not always depict ligand-receptor interactions accurately. In
fact, the flaw of the scoring system is considered to be a major limiting factor of
computational docking [282], especially for small ligands for which the number of
interactions between a ligand and its receptor is too small to make reliable
differentiations among different ligands. The docking programs make simplified
assumptions in the assessment of modelled complexes without accounting for physical
phenomena that play a role in influencing molecular recognition, such as entropic effects
[283]. For example, replacing the sulfur atom of the DAS structure with oxygen (DE)
should have resulted in similar or increased binding affinity. However, interestingly, we
observed lowest docking score for DE, when we would have expected this compound to
be at the least equally potent to DAS in its activity. Moreover, we expected increased
binding for the compounds in which modification have been made at the carbon atom
adjacent to the heteroatom by integrating stronger nucleophiles (e.g. PEXA). However,
we did not observe much increase in docking score for such analogs. Nevertheless, this
preliminary docking study provided some rough comparisons among the chosen ligands.
Inhibition of CYP2E1 activity by DAS and its analogs
There is very little information about the precise CYP2E1 inhibition capacity of
DAS. In a few studies, DAS has been shown to be a competitive inhibitor of CYP2E1
using human and rat liver microsomes [143, 284]. However, these studies were
performed either with insufficient or very low concentrations of DAS. In these studies,
the reported Ki values of DAS therefore differ by a large margin, perhaps due to the lack
of sufficiently varying degree of concentrations of both the inhibitor as well as the
substrate. The study by Morris et al used a couple of substrate and inhibitor
concentrations and provided a better inhibition kinetic profile. Moreover, at first, we
characterized the DAS inhibition kinetics with CYP2E1 using multiple concentrations of
both p-NP and DAS (Figure 2-2, Table 2-1).
We used CYP2E1 baculosomes for our study since they have the unique property
of expressing only one type of CYP isozyme. This gives an advantage over traditional
microsome-based assays in that there will be no interference/interactive effects from
other CYPs in determining the inhibition kinetics. First, we established that CYP2E1
activity is linear at 100 μM substrate concentration for one hour of reaction (data not
shown). We then conducted the inhibition assay at five different p-NP concentrations (5,
15, 30, 50, 100 μM) and six different concentrations of inhibitors (5, 10, 25, 50, 100, and
200 μM). Based on the reported Km value, 100 μM may not be the saturating p-NP
concentration. However, CYP2E1 shows substrate inhibition at >100 μM p-NP [281].
Therefore, first we performed the inhibition assay at 100 μM to obtain the IC50 values
(Table 2-1). Subsequently, we used lower concentrations of the substrate to determine
the IC50 at each substrate concentration as well as the Ki values. Our results showed that
DAS has an IC50 of 17.3 ± 1.1 μM and a Ki of 6.3 ± 1.0 μM, and it follows competitive
inhibition kinetics. Brady et al. used acetone-induced rat microsome for their study and
only one concentration of DAS (125 μM), and they observed that inhibition of CYP2E1
by DAS followed competitive inhibition, which is consistent with our findings
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Figure 2-2. Inhibition of CYP2E1 activity at varying p-NP substrate and inhibitor
concentrations.
The absorbance obtained without any inhibitor (vehicle only) was considered as 100%
CYP2E1 activity for each substrate concentration. The data was analyzed using nonlinear regression curve fitting. The IC50 was determined and presented in Table 2-1. The
data was also used to plot Michaelis-Menten kinetics curve and Ki as well as type of
inhibition were determined as described in Materials and Method.
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[143]. However, the reported Ki value (188 μM) from their study varies by a large margin
from our results as well as from the study conducted by another group using human and
rat microsome. Morris et al. reported an IC50 value of 3 μM for DAS. However, they
used only two lower concentrations (2 and 8 μM) [284]. The reported Ki values (0.3~1.9
μM) were also determined using limited concentrations of both DAS (0.25 and 1.0 μM
for human CYP2E1; 2 and 6 μM for rat CYP2E1) and the substrate. Our results are likely
to provide more accurate and reliable IC50 and Ki than the reported values, because we
used multiple substrate and DAS concentrations and used CYP2E1-induced baculosomes.
Furthermore, we performed a complete inhibition kinetics of seven DAS analogs
as described above (Figure 2-2, Table 2-1). Of the seven compounds, although AES
caused marked inhibition, it did not fit with any inhibition kinetics. Therefore, in
subsequent studies, we used only six compounds for complete inhibition kinetic analysis.
Results show that, contrary to the docking analysis, DE has significantly lower IC50 and
Ki values (6.3 ± 1.2* μM and 3.1 ± 0.2* μM, respectively) than DAS (17.3 ± 1.1 μM and
6.3 ± 1.0 μM, respectively). The analog with the highest docking score, TP, showed the
similar inhibitory capacity as compared to DAS (IC50 =19.4 ± 1.1 μM and Ki =7.7 ± 1.2
μM). AMS, which exhibited relatively higher docking score, showed an IC50 of 11.42 ±
1.1* μM and Ki of 4.4 ± 0.9 μM, which are lower than DAS. Similar to DAS, these
analogs showed competitive inhibition of the CYP2E1 activity. Thus AMS, TP, and DE
showed complete inhibition at saturating substrate concentration (Table 2-1), suggesting
that their nature of inhibition for CYP2E1 is similar to DAS. Other analogs- AES, 5,1
HA, PEA, and PEXA, despite having similar binding conformation and score, did not
exhibit desirable inhibitory activity and mostly followed un-competitive and/or noncompetitive inhibition kinetics.
As expected, the replacement of oxygen and/or changing the size of side chain of
DAS improved the binding of oxygen or sulfur with the heme of CYP2E1 and showed
better inhibition profiles with DE and AES than DAS. This mode of binding is expected
to produce metabolite by CYP2E1, which may be less toxic to the metabolites produced
by the oxidation of sulfur. It’s interesting to note that compounds that showed higher than
or similar to DAS binding affinity (IC50 or Ki) also showed similar inhibition kinetics to
DAS. However, the compounds that showed lower binding affinity than DAS showed
very different inhibition kinetics. These compounds appear to bind the CYP2E1 active
site in two different modes; one through oxygen and the other through nitrogen. The two
binding modes appeared to have weaken the overall binding affinity. We had initially
expected that nitrogen moieties on PEA, PEXA, and 5,1 HA is likely to strengthen the
binding of the heme of CYP2E1.
Conclusion
These results are significant in terms of finding a superior alternative to DAS.
Despite having substantial pharmacological activities and being used in numerous
research studies for many years, DAS has failed to consolidate its credibility to be a
potential drug candidate [120]. Due to its own toxicity, it is difficult to design any long
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term/chronic treatment schedule with DAS. The metabolites, diallyl sulfoxide and diallyl
sulfone, by undergoing further metabolic activation to their respective epoxides can cause
considerable toxicity. Moreover, these metabolites can cause autocatalytic destruction of
the CYP2E1 enzyme [120]. Zhai et al. has reported that DAS aggravated the isoniazid
induced toxic effect by potentiating increased ROS production in primary rat hepatocytes
[285]. Our own group have found that despite rescuing ethanol- mediated cell death to a
certain extent, DAS itself causes ~15% cell death in SVGA astrocytic cell lines in 24
hours [115]. The preliminary results (unpublished observations) with DAS analogs
showed that, even at as high as 200 μM concentrations, TP and DE did not show any
significant toxicities for six and four days of treatment, respectively. However, as
expected, DAS caused more than 40% cell death at 200 μM after two days of treatment.
In conclusions, this is the first report on a thorough analysis of CYP2E1 inhibition
kinetics of DAS and its seven structural analogs. This study provided two DAS analogs
that have better inhibition characteristics than DAS, which also appear to show relatively
lower toxicity than DAS in early studies. Our extensive toxicity profile study of these
compounds, and whether these compounds can rescue alcohol- and acetaminophenmediated toxicity in hepatic and extra-hepatic cells is underway. Overall the results are
very encouraging in the search for a superior alternative to the widely used DAS as a
selective CYP2E1 inhibitor as a research tool and/or as a possible combination/preventive therapy in alcohol- and other xenobiotic-mediated toxicity.
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CHAPTER 3. IN VITRO EVALUATION OF STRUCTURAL ANALOGS OF
DIALLYL SULFIDE AS NOVEL CYP2E1 INHIBITORS FOR THEIR
PROTECTIVE EFFECT AGAINST XENOBIOTIC-INDUCED TOXICITY AND
HIV REPLICATION3
Introduction
Garlic, one of the world’s most popular condiments, has a history of use for over
7000 years. Its culinary and medicinal properties are largely attributed to its complement
of organosulfur compounds. Diallyl sulfide (DAS) is one of the major organosulfur
compounds found in garlic, and it has been studied extensively as a preventive/protective
agent against various pathological conditions such as cancer, HIV-1, diabetes, and
Parkinson’s disease [120]. DAS has attracted major attention for its inhibitory action on
the cytochrome P450 2E1 (CYP2E1) enzyme and the resulting therapeutic/prophylactic
benefits. CYP2E1 is a key metabolic enzyme for many xenobiotics such as alcohol and
acetaminophen [39]. The inhibition of CYP2E1-mediated metabolism of these substrates,
especially in overdoses, is crucially important in preventing cytotoxicity.
At low physiological concentrations, ethanol is metabolized by the enzymes
alcohol dehydrogenase, catalase, and CYP2E1 [34]. However, at high concentrations,
ethanol-induced CYP2E1 plays the predominant role in ethanol metabolism [39]. This
results in increased production of reactive oxygen species (ROS) and other reactive
metabolites, thereby causing hepatic and extra-hepatic toxicity [39, 236, 237, 286, 287].
Ethanol can also induce CYP2E1 in extra-hepatic cells such as monocytes and astrocytes,
causing cytotoxicity to these cells due to increased metabolism and the resulting
oxidative stress. The widely-used analgesic acetaminophen (APAP), another CYP2E1
substrate, is one of the safest medications in use today. However, it can cause severe
hepatotoxicity at high doses though the CYP2E1-mediated metabolism of APAP and
formation of a toxic metabolite [258]. APAP overdose has affected millions of people
around the globe, especially in the United States, where it is the most common cause of
acute liver failure [288]. In addition, CYP2E1 has also been found to be involved in HIV1 replication and HIV-1/viral protein-mediated toxicity [120]. A recent study by our own
group has shown that CYP2E1 can be induced by viral proteins such as gp120 [141]. It
also suggests that the HIV-1 viral proteins may cause increased production of ROS and
reactive metabolites, consequently increasing the viral replication, possibly through the
induction of CYP2E1.
DAS is known to be a selective CYP2E1 inhibitor [120] Many in vitro and in vivo
studies have been conducted using DAS either to find the mechanistic pathways of
CYP2E1-associated toxic effects or to examine its efficacy as an inhibitor of CYP2E1
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[120]. However, DAS itself undergoes CYP2E1-mediated metabolism and produces toxic
sulfur metabolites. Thus, there is a potential risk involved in using DAS as a therapeutic
regimen. The challenge is to find a superior alternative to DAS with relatively low-tonegligible toxicity. We hypothesize that modification of the parent DAS structure would
result in analogs with improved CYP2E1 inhibition capacity and reduced cytotoxicity. In
our previous study, based on a computational ligand-docking analyses, we evaluated
seven structural analogs (allyl methyl sulfide, allyl ethyl sulfide, diallyl ether, thiophene,
2-(prop-2-en-1-yloxy) ethan-1-amine, 5-hexen-1-amine, and 2-prop-2-enoxyacetamide)
of DAS for their CYP2E1–inhibitory properties [289]. We found that two analogs (diallyl
ether and allyl methyl sulfide) had greater CYP2E1 inhibitory capacity than DAS, while
other analogs showed inhibitory capacity for CYP2E1 similar to DAS. In the current
study, we used those seven analogs to evaluate their in vitro cytotoxicity and their ability
to protect cells from ethanol- and APAP-mediated toxicity. We also tested these analogs
for their efficacy in suppressing HIV-1 replication.
Materials and Methods
Chemicals
The compounds tested in this study were all purchased from commercial sources.
Diallyl sulfide (purity 97%), allyl methyl sulfide (AMS, purity 98%), allyl ethyl sulfide
(AES, purity 98%), diallyl ether (DE, purity 98%), thiophene (TP, purity 95-98%), 2(prop-2-en-1-yloxy) ethan-1-amine (PEA, purity 95%), and 5-hexen-1-amine (5, 1 HA,
purity 95%) were purchased from Sigma-Aldrich (St. Louis, MO). 2-prop-2enoxyacetamide (PEXA, purity 95%) was purchased from Aldlab Chemicals (Woburn,
MA). The stock solutions for these compounds were prepared in dimethyl sulfoxide
(DMSO).
Cell culture and treatment
For this project, we used multiple relevant cell lines: human histiocytic lymphoma
U937 monocytes, SVGA immortalized astrocytes, and HepaRG hepatocytes. These cells
were used because CYP2E1 is constitutively expressed and is induced by ethanol leading
to cytotoxicity in these cells [39, 116, 290]. We also used latently HIV-infected
monocytic cells (U1 cells), which is considered the model system to study the effects of
HIV in monocytes [244]. The U937 cell lines were obtained from ATCC (Manassas,
VA). The U1 cell lines were obtained from the NIH AIDS Reagent Program
(Germantown, MD). Both cell lines were cultured in Roswell Park Memorial Institute
1640 media (Sigma Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum,
L-glutamine, sodium bicarbonate, non-essential amino acids, and gentamycin (for U937
cells) and penicillin-streptomycin solution (for U1 cells). The SVGA astrocytes were a
kind gift from Dr. Anil Kumar, University of Missouri-Kansas City (MO, USA), which
were originally developed by Major et al. [291]. The SVGA cells were cultured in
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Dulbecco's Modified Eagle Medium supplemented with the same nutrients (except Lglutamine) as U937 media. The terminally-differentiated HepaRG cells were maintained
in media prepared by the addition of the HepaRG Tox Medium Supplement® to 100 ml of
William’s Medium E (ThermoFisher Scientific, Grand Island, NY) and 1 ml of
GlutaMAX. All the cells were maintained in a humidified incubator with 5% CO2 at
37°C. To compare the cytotoxicity, the cells were treated with DAS and its analogs every
12 hours for 2 days (acute treatment) or 3-7 days (chronic treatment), with the addition of
fresh media during each treatment after the first one. DMSO (≤0.5%) treatment served as
the control condition for all experiments.
Determination of CYP2E1 activity in U937 monocytic and SVGA astrocytic cells
We demonstrated CYP2E1 enzymatic activity in U937 and SVGA cells. At first,
we extracted membrane proteins and membrane-associated proteins from these cells
using The Mem-PER Plus Kit following manufacturer’s protocol. Briefly, the cells were
permeabilized with a mild detergent to remove the soluble cytosolic proteins. A second
detergent was then added to solubilize the membrane proteins. After extraction, we
quantified the protein using the Pierce BCA protein assay kit. Finally, CYP2E1 activity
was determined using Vivid® CYP450 Screening Kit as described previously [245].
CYP2E1 baculosomes was used as positive control for this assay. All the above
mentioned kits were purchased from ThermoFisher Scientific (Grand Island, NY).
Measurement of reactive oxygen species (ROS) and cell viability using flow
cytometry
To determine the level of ROS and cell viability, U937 cells were treated with the
analogs, and quantification was performed using flow cytometry (BD Biosciences, San
Jose, CA). We used the fluorescence dye 5-(and-6)-chloromethyl 2’,7’dichlorodihydrofluorescein diacetate (CM-H2DCFDA) (Life Technologies, Oregon,
USA) for ROS measurement and Ghost dye (Tonbo Biosciences, San Diego, CA) for cell
viability. After 48 hours of treatment, the cells were collected and washed with PBS. The
cells were resuspended in PBS containing 2.5 μl of CM-H2DCFDA and 1 μl of Ghost
dye. They were incubated at 37°C without light for 30 minutes. After incubation, the cells
were washed, resuspended in 300 μl of PBS, and ROS and cell viability were measured.
The data were analyzed using BD FACS software (version 8).
XTT cell viability assay
Cell viability was also measured using the XTT cell viability assay kit (Cell
Signaling Technology Inc., Danvers, MA). In brief, 200 μl of the media containing
treated cells were collected and 50 μl of XTT detection solution was added into each well
of a 96-well plate. The plate was incubated for 2-3 hours in an incubator at 37°C. The
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resulting absorbance, corresponding to relative viability, was measured at 450 nm using a
Cytation 5 micro plate reader.
LDH activity assay
Cytotoxicity was also evaluated using the Pierce Lactate Dehydrogenase (LDH)
Cytotoxicity Assay Kit (ThermoFisher Scientific, Grand Island, NY). LDH assay is a
convenient method to measure cell viability in adherent cells. LDH is released into the
media from damaged cells which indicates cytotoxicity and cytolysis. Briefly, 50 μl of
the treated media (in triplicates from each well) were collected into a 96-well plate and
mixed with 50 μl of the LDH reaction mixture. After 30 minutes of incubation at room
temperature, the reaction was terminated by adding LDH stop solution. The absorbance
was measured at 490 nm and 680 nm using the Cytation 5 micro plate reader.
Caspase-3 activity assay
Activation of the caspase-3 pathway is a hallmark of apoptosis. To measure
caspase-3 activity in the treated cells, we used a caspase-3 colorimetric assay kit
(BioVision, Inc., Milpitas, CA). After treatment, the cells were lysed using cell lysis
buffer and protein was extracted. Then the protein concentration was determined using
the BCA Protein Assay Kit (Pierce Biotechnology, Waltham, MA). About 50-100 μg of
the protein was diluted to a final volume of 50 μl in lysis buffer. Later, 50 μl of 2X
reaction buffer (containing 10 mM DTT) and 5 μl of 4 mM DEVD-pNA substrate was
added and incubated at 37°C for 1 hour in darkness. The absorbance was measured by
using a Cytation 5 micro plate reader at a wavelength of 405 nm.
HIV p24 ELISA
Suppression of the viral load was measured by using the p24 ELISA kit
(ZeptoMetrix Corp, Buffalo, NY). The U1 cells were treated with the analogs and media
was collected after 48 hours of treatment. The viral p24 group-specific antigen was
specifically captured with a monoclonal antibody and then reacted with a high titered
human anti-HIV-1 antibody conjugated with biotin. After incubating the sample with
streptavidin-peroxidase, absorbance was measured using a micro plate reader. The OD
value is proportional to the viral p24 load in the sample.
Statistical analysis
Data were analyzed using GraphPad Prism 5 software (GraphPad Software Inc.,
San Diego, CA). Data in this manuscript for all experiments are presented as mean ±
SEM of 3-6 experimental replicates. One-way ANOVA was used for comparisons
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between different treatment groups and p-values of ≤0.05 were considered statistically
significant.
Results and Discussion
We hypothesize that the modification of the parent DAS structure will not only
improve the CYP2E1 inhibitory capacity of the analogs but will also reduce the potential
toxicity at high concentrations. It is known that the sulfur hetero atom in the DAS
structure interacts with the CYP2E1 active site and thereby acts as a competitive inhibitor
[292]. However, this same phenomenon is also responsible for producing the toxic sulfur
metabolites [120]. To find a superior alternative, we performed a structure-activity
relationship study. We chose the commercially available DAS structural analogs in such
a way that it would maintain its capacity to inhibit CYP2E1 while no longer being a
substrate. The selected DAS analogs had either the oxygen as a hetero atom in place of
sulfur (DE, PEA, and PEXA) or lacked the hetero atom completely (5,1 HA). These
substitutions/deletion are likely to result in producing a non-toxic metabolite or no
metabolite at all, mainly due to the absence of sulfur atom in the structure [120]. We also
chose a DAS analog that had a stronger nucleophile at the carbon atom adjacent to the
hetero atom (PEA, PEXA, and 5,1 HA). These alterations in DAS analogs are expected to
result in improving their toxicity profiles. Furthermore, smaller side chains (AMS and
AES) have been reported to increase the binding efficiency to the active site [120].
Unlike the other CYP enzymes, the binding site of the CYP2E1 lies in a narrow channel
[293]. Hence, a low molecular weight cyclic compound (TP) is expected to work as a
potent inhibitor but not as a substrate due to its cyclic structure. Our inhibition study
showed that two analogs (DE and AMS) were stronger CYP2E1 inhibitors than DAS, TP
had a similar inhibitory capacity to DAS, and the other analogs showed moderate
CYP2E1 inhibition [294]. Despite the differences in the magnitude of their inhibition, we
included all seven analogs for this in vitro toxicity and efficacy study. We used four
different cells for this project: U937 monocytes, U1 monocytes, SVGA astrocytes, and
HepaRG hepatocytes.
CYP2E1 activity in U937 monocytic and SVGA astrocytic cells
To demonstrate the efficacy of the DAS analogs as CYP2E1 inhibitor, we used
three CYP2E1 expressing relevant cell lines in this study. Among them, HepaRG is a
well-established terminally differentiated cell lines that mimics the characteristics (e.g.
CYP expression) of the primary hepatocytes. In a separate study, we have shown that
CYP2E1 is expressed in high level in HepaRG cells [48]. However, CYP2E1 is
expressed in lesser magnitude in monocytic and astrocytic cells compared to hepatocytes.
In our previous studies, we observed substantial CYP2E1 mRNA and protein level in
U937 and SVGA cells [272, 295]. Since there is no report of CYP2E1 enzymatic activity
in these cells, in this study, we examined CYP activity in these cells as described in
Materials and Methods. We obtained around 100±10 μg of protein from 5 million U937
cells and 180±10 μg of protein from 7-8 million SVGA cells. We used various amount of

42

protein to determine the concentration dependent increase in activity. The data showed
that in both cell lines, CYP2E1 activity increased with time- and protein concentrationdependent manner (data not shown). CYP2E1 activity in U937 cells was comparatively
higher than that in SVGA cells, which is consistent with our previous finding for
CYP2E1 mRNA and protein levels in these cell lines [40]. CYP2E1 baculosomes showed
linear increase in activity with time. This data justifies the use of these two cell lines for
this current study, along with the HepaRG cells which resembles many characteristics of
primary hepatocytes.
Effect of acute treatment of DAS analogs on cytotoxicity
At first, we conducted a time and concentration-dependent cytotoxicity study in
U937 cells using the following commercially available analogs: DE, TP, AMS, and AES.
We used this cell line to optimize time and concentration, because it is easily available
and cost-effective compared to primary cells. We treated the U937 cells with 10-200 μM
of DAS and its analogs for up to 48 hours. Using flow cytometry, we observed that DAS
caused significant cytotoxicity at 50 μM, whereas DAS analogs did not show detectable
toxicity (Figure 3-1A). At higher concentrations, e.g. 200 μM, DAS caused severe
toxicity, whereas DE, TP, and AMS did not cause significant toxicity. We also measured
the level of ROS. The results showed that DAS as well as its analogs did not cause
increased ROS (Figure 3-1B). The results suggest that DAS and its analogs do not cause
cytotoxicity through the oxidative stress pathway.
We performed further investigation using three other custom-made DAS analogs:
PEA, PEXA, and 5,1 HA. Since 200 μM DAS caused maximum cytotoxicity, we used
only this concentration with the custom-made DAS analogs (Figure 3-2). Using the XTT
cell viability assay, we observed that after 48 hours of treatment, DE, TP, AMS, and
PEXA did not cause any significant cytotoxicity in monocytes, astrocytes, or hepatocytes.
The results further suggest that all the DAS analogs tested have better toxicity profiles
than DAS, at least for acute treatment in both hepatic and non-hepatic monocytic and
astrocytic cells.
Effect on caspase-3 activity
It has been reported that DAS is metabolized to reactive metabolites and cause
toxicity through the caspase-3-dependent apoptotic pathway [296]. To determine whether
the new DAS analogs show a lack of toxicity as a result of limited metabolism of these
analogs into toxic species and subsequent lack of caspase-3 cleavage activation, we
treated the U937 cells with 200 μM DAS analogs and measured caspase-3 activity. We
observed that DAS, as expected, caused a ~2-fold increase in caspase-3 activity, whereas
the DAS analogs did not cause any increase in activity (Figure 3-3). The results suggest
that the DAS analogs do not induce caspase-3 apoptotic pathway.
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Figure 3-1. Effect of acute treatment on cell viability and ROS production in
monocytes.
A) U937 cells were treated with DAS and the commercially available analogs DE, AES,
AMS, and TP for 48 hours. Cell viability was quantified by flow cytometry. DAS caused
severe toxicity at higher concentrations whereas DE, TP, and AMS did not show
significant toxicity up to 200 μM. B) ROS production was quantified by flow cytometry.
The mean fluorescent intensity (MFI) indicates the level of ROS. * indicates significance
(p<0.05) compared to control, # indicates (p<0.05) compared to DAS.
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Figure 3-2. Effect of acute treatment on cell viability in monocytes, astrocytes,
and hepatocytes.
A) The structure of the commercially available DAS analogs. B, C, and D) Cell viability
in U937, SVGA, and HepaRG cells after 48 hour of treatment, as measured by XTT cell
viability assay. * indicates significance (p<0.05) compared to control, # indicates
(p<0.05) compared to DAS.
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Figure 3-3. Effect on caspase-3 activity after treatment with DAS and its analogs.
U937 cells were treated with 200 μM of these compounds for 48 hours and caspase-3
activity was measured by colorimetric assay. * indicates significance (p<0.05) compared
to control, # indicates (p<0.05) compared to DAS.
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Effect of chronic treatment on cytotoxicity with the selected DAS analogs
One of the major concerns related to the use of DAS as a research tool or potential
adjuvant therapy is that it has the potential to cause toxicity over an extended period,
even at relatively low concentrations. Therefore, we performed a chronic treatment study
using U937 cells. We treated the cells with varying concentrations (5-200 μM) of the
analogs for up to 7 days and visually examined cell viability every 24 hours under the
microscope (Figure 3-4A). In addition, we performed XTT cell viability assays on day 4
and day 7. The results showed that on the fourth day of treatment, all the analogs were
significantly less cytotoxic than DAS at 200 μM (Figure 3-4B). After seven days of
treatment, the analogs showed some degree of toxicity at higher concentrations (100 and
200 μM), but still significantly less toxicity than DAS. We also treated the HepaRG
hepatocytes at 200 μM DAS and its analogs. We observed that DE, TP, 5,1 HA, PEA,
and PEXA did not show any toxicity after 7 days of treatment. The results suggest that
the new analogs have better toxicity profiles than DAS for even longer treatment
regimens.
Protective effect of the analogs from ethanol-induced toxicity
Upon establishing the relative toxicity profiles of the novel DAS analogs using an
in vitro system, we evaluated their efficacy in preventing xenobiotic-mediated toxicity
and HIV-1 replication. Besides DAS being known as a selective CYP2E1 inhibitor, many
studies have also shown that DAS administration induces anti-oxidant enzymes by
modulating the Nuclear factor-erythroid 2 related factor 2 (Nrf2) pathway, which plays
crucial role in maintaining redox homeostasis [124, 297]. Moreover, DAS has been
shown to increase the reduced glutathione (GSH): oxidized glutathione (GSSG) ratio,
which is indicative of increased antioxidant capacity [57]. We hypothesize that due to
analogous chemical structure and CYP2E1 inhibitory property, the new DAS analogs will
exert their protective function by inhibiting CYP2E1 mediated metabolism as well as by
inducing antioxidant capacity. At first, we used these analogs to determine whether they
can rescue ethanol-induced toxicity. Among all the alcohol-related disorders, alcoholic
hepatitis is considered as the most severe form of alcohol-induced liver injury [298].
Unfortunately, there is currently no effective treatment regimen available on the market.
Nearly half the patients suffering from alcoholic hepatitis do not benefit from the
treatment [299]. Therefore, it is of critical importance to intervene the progression of
ethanol-induced liver injury by taking preventive measures. CYP2E1-mediated ethanol
metabolism and oxidative stress have been implicated as major contributors to alcoholrelated liver injury. CYP2E1 is also induced by ethanol, which further exacerbates tissue
injury [39]. Ethanol can cause damage in the case of both regular/social and binge
drinking scenarios.
We co-treated HepaRG hepatocytes with 50 mM ethanol (~physiological
concentration in binge and/or chronic drinking) and 50 μM of the novel analogs for 48
hours.
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Figure 3-4. Effect of chronic treatment on cell viability in monocytes and
hepatocytes.
U937 cells were treated with varying concentrations of DAS, TP, AMS, DE, and PEXA
for 4-7 days. A) Microscopic images of the U937 cells of different treatment groups were
taken on days 1, 4, and 7. B) Cell viability was quantified by XTT assay. * indicates
significance (p<0.05) compared to 5 μM of the respective analog. C) Hepatocytes were
treated with 200 μM of the compounds for seven days. Cell viability was quantified by
XTT cell viability assay. * indicates significance (p<0.05) compared to control, #
indicates (p<0.05) compared to DAS.
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We optimized the concentration of DAS and its analogs based on our results from
toxicity study, which showed that DAS was toxic at 50 μM concentration, whereas the
novel analogs did not cause any significant toxicity at 50 μM. Since the objective of this
study was to find a suitable alternative to DAS which can be used at higher concentration
for longer duration, we used this concentration to assess whether the new analogs can
protect the hepatocytes from alcohol induced toxicity. The XTT cell viability assay
showed that compared with DAS, DE, TP, AMS, PEA, and PEXA rescued ethanolinduced toxicity (Figure 3-5A). We also co-treated the cells with 20 mM ethanol
(~physiological concentration in regular/social drinking) and 20 μM of the analogs for 48
hours, expecting that DAS would prevent ethanol-induced toxicity at a lower dose. We
performed LDH cytotoxicity assay as a cytotoxicity marker for this experiment. Upon the
damage of cell membrane, LDH is released into the cell culture media and indicates
cytotoxicity. As expected, DAS rescued ethanol-mediated toxicity. However, TP, AMS,
and PEXA showed even higher magnitudes of rescue for ethanol-induced toxicity than
DAS (Figure 3-5B). Overall, these results are encouraging in the search for a better
alternative to DAS in preventing ethanol-induced toxicity.
Protective effect of DAS analogs from acetaminophen-induced toxicity
Our next goal was to evaluate the efficacy of these DAS analogs in preventing
APAP-induced toxicity. At elevated levels, CYP2E1-mediated metabolism of APAP
produces the toxic metabolite- NAPQI, which potentiates liver injury. We co-treated the
cells with 0.5 mM APAP and 20 μM of the analogs for 4 days. We measured the LDH
activity in the media, which is indicative of enhanced cytotoxicity, every 24 hours for
four days (Figure 3-6). Despite DAS being a CYP2E1 inhibitor, it did not rescue APAPmediated toxicity, but rather increased the toxicity further with APAP. However, TP,
AMS, DE, PEA, and PEXA rescued APAP-induced toxicity. Furthermore, DAS showed
a time-dependent increase in APAP-mediated toxicity, with severe toxicity after 4 days.
However, TP, AMS, and DE showed protective effect against APAP even after 4 days of
exposures. This further suggests that DAS is not an ideal CYP2E1 inhibitor to rescue
APAP-mediated toxicity for chronic exposure. However, the DAS analogs do have the
potential to inhibit CYP2E1 and rescue toxicity caused by chronic APAP exposure.
Suppression of viral p24 antigen by DAS analogs
HIV-1 viral proteins (e.g. gp120) have been implicated to increase HIV-related
toxicity by inducing the CYP2E1 enzyme. Induction of CYP2E1 can result in increased
oxidative stress and cytotoxicity via the metabolism of endogenous compounds, which in
turn can increase viral replication [141]. We treated U1 (HIV-infected U937) monocytic
cells with 20 μM of the analogs. The results clearly demonstrated that the use of a
CYP2E1 inhibitor can help reduce the viral load (p24) in the HIV-infected population.
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Figure 3-5. Rescue from ETH-induced toxicity in HepaRG hepatocytes.
A) Cells were co-treated with 50 mM ethanol and 50 μM of DAS and its analogs for 48
hours. XTT cell viability assay was performed to measure cell cytotoxicity. B) Cells were
co-treated with 20 mM ethanol and 20 μM of the compounds for 48 hours. LDH activity
assay was performed to evaluate comparative cytotoxicity. * indicates significance
(p<0.05) compared to control, £ indicates (p<0.05) compared to ethanol (ETH), #
indicates (p<0.05) compared to DAS+ETH.
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A

Figure 3-6. Rescue from APAP-induced toxicity in HepaRG hepatocytes.
A, B, C, and D) Cells were co-treated with 0.5 mM ethanol and 20 μM of DAS and its
analogs for 48, 72, 96, and 120 hours. Cytotoxicity was measured by LDH activity assay.
* indicates significance (p<0.05) compared to control, £ indicates (p<0.05) compared to
APAP, # indicates (p<0.05) compared to DAS+APAP.
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DAS, TP, AMS, and DE significantly lowered the viral load relative to the untreated
control (Figure 3-7). In addition, TP and DE showed higher viral suppression than DAS,
suggesting that these DAS analogs have better capability to suppress HIV-1 replication
than DAS. This is an important finding that CYP2E1 inhibitors can reduce HIV
replication.
Conclusion
Based on the results discussed above, we conclude that we have identified several
analogs of DAS, especially TP, AMS, and DE. These compounds appear to be less toxic
than DAS for the cellular models evaluated in this project. This is the first report of an
extensive in vitro toxicity profile study of DAS and its analogs using hepatic and extrahepatic cells. Our next goal is to evaluate the pharmacokinetic and pharmacodynamic
properties of these DAS analogs using an appropriate animal model. Upon further
analysis, these analogs may replace DAS as a research tool and/or potential therapeutic
regimen for preventing xenobiotic-induced toxicity and viral suppression. Despite having
many therapeutic properties, the usage of DAS is restricted due to its toxicity. Therefore,
there was a critical need for replacing DAS with a safer CYP2E1 inhibitor.

Figure 3-7. Suppression of viral load by DAS and its analogs in U1 cells.
Viral p24 load was quantified by p24 ELISA. * indicates significance (p<0.05) compared
to control.
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CHAPTER 4. PLASMA EXOSOMES EXACERBATE ALCOHOL- AND
ACETAMINOPHEN-INDUCED TOXICITY VIA CYP2E1 PATHWAY4
Introduction
Cytochrome P450 (CYP) enzymes are key components in drug metabolism and
xenobiotic- induced toxicity. At high doses, oxidative stress and formation of toxic
metabolites mediated by CYP2E1 are known as the principal pathway of toxicity induced
by alcohol (ALC) and acetaminophen (APAP) [259, 300-302]. Ethanol-induced oxidative
stress is not restricted to the hepatic cells, where ethanol is actively oxidized, but can
affect various extra-hepatic tissues [34, 115, 287]. Since CYP2E1 is expressed in lower
magnitude in the extra-hepatic regions than in the liver, the drug overdose-associated
toxicity is not always clearly understood in extra-hepatic cells. Previously, we have
shown that alcohol exposure increases human immunodeficiency virus (HIV) replication
in monocytic cells via CYP2E1-mediated oxidative stress [237, 303]. However, the exact
mechanism of alcohol exacerbated HIV replication in monocytic cells via CY2E1mediated oxidative stress is not clear.
Literatures suggest a potential contribution of exosomes as a key modulator in
xenobiotics- and disease-induced toxicity in various tissue systems [304, 305].
Exosomes, the small extracellular nanovesicles produced by most cell types, are
emerging as a novel tool for investigation of disease pathogenesis and drug discovery
research [266, 306-309]. Exosomes can play a vital role in intra- and intercellular
communication via selective packaging and transport of microRNAs (miRNAs), mRNAs,
proteins, and other biological cargos to neighboring cells or to distant tissues via biofluids
such as plasma, urine, cerebrospinal fluid, etc. [310-314]. Their unique ability to navigate
through the biological system, transport important biomolecules, and influence the
pathophysiology in the recipient cells make exosomes an attractive candidate for
biological and biopharmaceutical research [315-317]. Recently, plasma exosomes have
been studied extensively to discover reliable biomarkers for diseases such as cancer,
kidney injury etc. [317-320]. Exosomes in plasma are secreted from a variety of tissues,
and therefore, they are an excellent resource for examination of disease pathogenesis.
The presence of some of the most physiologically relevant CYP enzymes,
including CYP2E1, in human plasma exosomes was recently reported by our group
[321]. We observed that exosomes derived from plasma of healthy subjects packaged
metabolically active CYP2E1 as well as other CYP isoforms. Interestingly, the level of
CYP2E1 mRNA and protein level in plasma exosomes were significantly higher than the
other CYPs such as CYP3A4. A recent report by our group demonstrated that there are
significant differences in the packaging of inflammatory cytokines
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(e.g. interleukins- 6, 8, 10) in plasma exosomes isolated from HIV-infected ALC drinker
[187]. Exposure of ALC or APAP to hepatic cells induces CYP2E1 and potentially
increases packaging of CYP2E1 in exosomes [38, 115, 322]. Therefore, we hypothesized
that these exosomes can transfer CYP2E1 to extra-hepatic tissues via biological fluids
and mediate ALC- and APAP-induced toxicity.
In this study, we examined whether plasma exosomal CYP2E1 cargo play a role
in exacerbating ALC- and APAP-induced toxicity in hepatic and extra-hepatic cells.
Materials and Methods
Chemicals
Acetaminophen (catalog #A5000-100G) and diallyl ether (purity 98%, catalog #
259470) were purchased from Sigma-Aldrich (St. Louis, MO). Two hundred proof
ethanol (catalog #A405P4) was purchased from Fisher Scientific (Hampton, NH).
Cell culture and treatment
For the current study, two types of cell lines were used: 1) HepaRG hepatocytes
and 2) latently HIV-1-infected monocytic U1 cells. Terminally differentiated HepaRG
cells (ThermoFisher Scientific, Grand Island, NY) are the most reliable and appropriate
cell lines for hepatocyte research due to their similar expression profile of CYPs and
other metabolic enzymes when compared with primary hepatocytes [323]. The U1 cells
(NIH AIDS Reagent Program; Germantown, MD) are recognized as the model system for
investigating HIV effects in monocytes [324]. HepaRG cells were cultured in media
consisting of William’s E Medium supplemented with HepaRG Tox/Maintenance
Medium Supplement® and Glutamax. First, the cells were plated using maintenance
media. After 24 hours, maintenance media was replaced with tox media and cells were
allowed to reconstitute in monolayer. The treatment was started at the 7th day since the
peak CYP expression occurs from day 7-10. The U1 cells were cultured in Roswell Park
Memorial Institute (RPMI) 1640 media (Sigma Aldrich, St. Louis, MO) supplemented
with 10% fetal bovine serum, L-glutamine, sodium bicarbonate, non-essential amino
acids, and penicillin-streptomycin solution. The cells were maintained in a humidified
incubator with 5% CO2 at 37°C. Cells were co-treated with either 50 mM ethanol or 0.5
mM acetaminophen along with isolated human or mouse plasma exosomes for 1 - 8 days.
We used the CYP2E1 inhibitor diallyl ether (20 μM) to validate the role of plasma
exosomal CYP2E1 in ALC- or APAP-induced toxicity. Cell culture media was collected
for use in the LDH cell viability assay and replaced with an equivalent amount of fresh
media. At the end of treatment, cells were harvested for performing protein extraction
and western blot assay.
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Isolation and validation of exosomes from human and mouse plasma
Exosomes were isolated from both human and mouse plasma for this project.
Human blood samples were collected from de-identified healthy individuals at Interstate
Blood Inc. (Memphis, TN). Exosomes were isolated using the Plasma Exo Kit (Applied
Biosystems, Foster City, CA). In brief, a 0.22 μm filter was used to remove larger
vesicles (>200 nm) from the plasma. Afterwards, the human and mouse samples were
centrifuged at 2,000 and 10,000 g, respectively for 20 min to remove cell debris. To the
clarified plasma, 0.5 volume of 1X PBS was added and mixed thoroughly. Afterwards,
0.2 volume of exosome precipitation reagent was added, and the samples were mixed
well by vortexing. After a 10 min incubation at room temperature, samples were
centrifuged at 10,000 g for 5 min. The resulting pellet was resuspended using appropriate
medium and used for downstream procedures. We checked for expression of the standard
exosomal marker proteins such as CD63 and CD81 by western blotting. We also tested
whether plasma exosomes contained a liver-specific HP protein, since the liver is one of
the major contributors of plasma exosomal CYP enzymes. Exosomes were also validated
in terms of size, shape, and quality by using Transmission Electron Microscopy,
following a standard protocol as described previously [325] (JEOL 2000EXII TEM,
Neuroscience Institute, The University of Tennessee Health Science Center).
Acetylcholine esterase assay
The quality of the isolated exosomes was further verified by measuring
acetylcholinesterase activity using the validated AmplexTM Red
Acetylcholine/Acetylcholinesterase Assay Kit (Molecular Probes, Invitrogen). In brief,
exosome pellets were resuspended in 100 μl of 50 mM Tris-HCl (pH 8.0) and incubated
with 100 μL of the Amplex Red reagent containing 2 U/mL HRP, 0.2 U/mL choline
oxidase, and 100 μM acetylcholine in a final volume of 200 μL. Acetylcholinesterase and
H2O2 solution were used as a positive control. The reaction plate was incubated in the
absence of light for an hour at room temperature. Fluorescence measurement was taken
every 15 min at a wavelength of 530 nm (λex) and 590 nm (λem), respectively.
Animal treatment
In the present study, we used 10- to 12-week old C57BL/6 female mice. The
animal study protocol was approved by the Institutional Animal Care and Use Committee
(IACUC, approval number 18-086) of the University of Tennessee Health Sciences
Center (Memphis, TN, USA). Mice were divided into two groups, a control (n=6) and a
treatment group (n=6). The control mice received Lieber-DeCarli control liquid diet and
the treatment group mice received a single dose of ethanol (5 g kg−1). The animals were
sacrificed at the end of the study and blood was collected to isolate plasma. Further, we
isolated exosomes from plasma using a validated exosome isolation kit (Invitrogen, Life
Technologies, NY) and characterized as described in the preliminary study and previous
reports [321].
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Exosomes labeling and uptake
After treating cells with isolated plasma exosomes, the cellular uptake of the
exosomes was measured by using Exo-GLOWTM Exosome Labeling Kits (System
Biosciences, CA). Exosome pellets containing 100-500 μg protein were resuspended in
500 μl of 1X PBS. Next, 50 μl of 10X Exo-Green fluorescent label was added to the
solution, mixed well by inversion, and incubated at 37 °C for 10 min. To this mixture,
100 μl of ExoQuick-TC reagent was added (mixed by inversion) to stop the labeling
reaction and kept on ice (or at 4 °C) for 30 minutes. The samples were centrifuged at
16000 g for 3 minutes and the washed pellet was resuspended in 500 μl of 1X PBS. The
labeled exosome suspensions were exposed to hepatocytes and their uptake was
monitored by fluorescence microscopy.
SiRNA transfection and treatment
We blocked CYP2E1 expression in HepaRG cells by transfecting the cells with
predesigned human CYP2E1 siRNA or scrambled siRNA, followed by exosome
treatment. Following 72-hour incubation with lipofectamine transfection reagent in
serum-free and antibiotic-free media, siRNA-transfected cells were treated with plasma
exosomes ± ALC and toxicity was compared with non-transfected treatment group to
measure the specific contribution of plasma exosomal CYP2E1 in enhancing ALCinduced toxicity. Toxicity was measured by LDH assay.
Western blot
Protein expression in the exosomes derived from human and murine plasma was
determined by western blotting. Protein quantification was carried out by using a
Pierce™ BCA protein assay (ThermoFisher Scientific, Grand Island, NY) as described
before. Approximately 10 μg of protein was loaded into a polyacrylamide gel. The gel
was run for 90 min at 150 V, which separated the proteins based on their molecular
weight. To transfer the proteins from the gel to a polyvinyl fluoride membrane, gel was
run for 90 minutes at 0.35 Amp. After the proteins were transferred to the membrane, it
was blocked with 5–10 ml of Li-Cor blocking buffer (LI-COR Biosciences, Lincoln, NE)
for 60 minutes to prevent the nonspecific binding of antibodies to its surface. The
membrane was then incubated overnight with primary antibodies (CD63 rabbit Mab,
1:400 dilution, Proteintech catalog #25682-1-AP; CD81 rabbit Mab 1:400 dilution, Santa
Cruz Biotechnology, catalog #sc-9158; HP rabbit Mab, 1:500 dilution, Proteintech,
catalog #16665-1-AP ; CYP2E1 rabbit Mab, 1:400 dilution, Millipore, catalog #AB1252;
SOD1 mouse Mab, 1:200 dilution, Santa Cruz Biotechnology, catalog #sc-101523;
Catalase rabbit Mab, 1:400 dilution, Proteintech, catalog #21260-1-AP) at 4 °C. The
membrane containing blots was washed with PBS containing 0.2% Tween-20 several
times before incubating with the corresponding secondary antibodies for 1 h at room
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temperature, protected from light. The Image Studio Lite version 4.0 in a Li-Cor Scanner
(LI-COR Biosciences) was used to scan the membrane blots. The fold change in the
expression of proteins was calculated based on densitometry data obtained from the
Image Studio Lite software.
LDH cell viability assay
Cytotoxicity was measured using the Pierce Lactate Dehydrogenase (LDH)
Cytotoxicity Assay Kit (ThermoFisher Scientific, Grand Island, NY) following the
manufacturer’s protocol. Release of LDH into the cell culture media is an indicator of
cytotoxicity and cytolysis. In brief, 50 μl of the collected media were mixed with 50 μl of
the LDH reaction mixture in a 96-well plate. After incubating at room temperature for 30
minutes, the reaction was stopped by adding LDH stop solution. Using a micro plate
reader (Cytation™ 5 Cell Imaging Multi-Mode Reader, BioTek, VT), the absorbance was
measured at 490 nm and 680 nm. Higher absorbance indicated higher toxicity.
Statistical analysis
Data analysis was carried out using GraphPad Prism 5 software (GraphPad
Software Inc., San Diego, CA). All the data are presented as mean ± SEM of 3-6
experimental replicates. One-way ANOVA followed by Tukey’s post hoc test was used
for comparisons between different treatment groups and p-values of ≤0.05 were
considered statistically significant.
Results
Identification and characterization of plasma exosomes and uptake of exosomes in
the recipient cells
We isolated exosomes from healthy human plasma as previously described and
characterized their physicochemical properties[48, 325]. Transmission electron
microscopy (TEM) images confirmed the presence of exosomes (double-membraned
vesicles) in the prepared sample (Figure 4-1A). Further, we showed a time-dependent
increase in acetylcholine esterase activity (Figure 4-1B) and the presence of CD63 and
CD81 (Figure 4-1C), which are specific markers for exosomes, confirming the
identification of exosomes. Further, we showed the presence of haptoglobin (HP)
(Figure 4-1C), a specific marker protein for hepatocyte-derived exosomes, suggesting
the presence of liver-derived exosomes in the plasma. Since liver is the powerhouse of
CYP enzymes, it is likely that the majority of the CYP enzymes in the plasma exosomes
are secreted from the liver. Moreover, CYP enzymes in plasma exosomes may come
from a variety of other cells as well since CYPs are also expressed in many extra-hepatic
tissues such as lung, kidney, etc. Previously, we have shown that plasma exosomes
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Figure 4-1. Identification of exosomes derived from human plasma.
A) Transmission electron microscope (TEM) images of exosomes (arrows indicate
exosomes). B) Acetylcholinesterase activity in exosomes. C) Representative
immunoblots for the expression of exosomal marker protein CD63 and CD81, and liver
specific exosomal protein HP in plasma exosomes. Equal amount of protein (10 μg) was
loaded in each lane. D) Bright field, fluorescent, and overlay images of cells after 3 and 6
hours of exosomes exposure. Microscope was set to visualize particles of ≤200 μm
diameter. Bright field and fluorescent images represent only cells and cells with
exosomes, respectively. Overlay images demonstrate the presence of exosomes within the
cells.
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contain substantial amount of CYP2E1 mRNA and protein in healthy human donor[48].
In this study, we also found that plasma exosomes from two healthy donors contained
significant level of CYP2E1 protein (Figure 4-1C).
To determine whether the exosomes are involved in cell-cell communication, we
performed an exosome uptake assay. In this study, we used HepaRG hepatocytes and the
HIV-1-infected monocytic U1 cell line. HepaRG cells are considered a reliable in vitro
model for studying hepatic drug metabolism and liver-related pathologies. They express
the majority of phase I and II metabolic enzymes, including CYP2E1, and CYP2E1 is
further induced by ALC in HepaRG cells [326-328]. Similarly, among extra-hepatic cells,
HIV-infected monocytic cells (U1) express cellular CYP enzymes, especially CYP2E1
and are induced by ALC exposures [115, 237]. We exposed plasma exosomes to HepaRG
cells. As shown previously [325] with U1 cells, our fluorescence microscopy imaging
showed that exosomes are readily taken up by the recipient hepatocytes after 3-6 hours of
exposure (Figure 4-1D).
Effect of human plasma exosomes on hepatocytes upon ALC and APAP exposure
In our previous study, we observed that plasma exosomes contain large amounts
of CYP2E1 enzyme relative to hepatocytes or hepatocyte-derived exosomes [48]. To
investigate the effect of plasma exosomal CYP2E1, we co-treated HepaRG cells with
exosomes (derived from 50 μL of clarified plasma) along with 50 mM ALC and 0.5 mM
APAP. As expected, both ALC and APAP showed time-dependent increase in toxicity in
HepaRG cells, which are known to be mediated through CYP2E1 pathway. We further
observed that treatment with plasma exosomes caused a significant increase in ALCinduced toxicity in a time-dependent manner (Figure 4-2A). Similarly, plasma exosome
exposure resulted in increased APAP-induced toxicity (Figure 4-2B). These results
suggested that CYP2E1 cargo in plasma exosomes may contribute to the toxicity induced
by ALC and APAP. It is important to note that plasma exosomes treatment alone caused
significant toxicity from 5th day onwards, perhaps due to increased metabolism of
endogenous substrates as well as delivery of oxidative stress related miRNA (e.g. mir200
family) resulting in enhanced oxidative stress and cytotoxicity.
The role of plasma exosomal CYP2E1 in mediating ALC- and APAP-induced
toxicity
To examine whether plasma exosomal CYP2E1 contributes to ALC- and APAPinduced toxicity, we pretreated the hepatic cells with selective CYP2E1 inhibitor and
siRNA. In our laboratory, we have identified several analogs of diallyl sulfide (DAS) as
more potent and relatively safer CYP2E1 inhibitors. Diallyl ether (DE) is one of the
analogs with the best CYP2E1 inhibitory capacity and lowest toxicity profile [289, 329].
We pretreated HepaRG cells with ALC and/or APAP and plasma exosomes with or
without pre-treatment with DE. In both set of treatments, we observed that DE
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Figure 4-2. Effect of plasma exosomal CYP2E1 in HepaRG cells upon ALC and
APAP treatment.
Plasma exosomes were isolated from healthy human plasma and then treated to HepaRG
cells ± ALC and APAP (panel A & B respectively). EXO1 and EXO2 represent
exosomes isolated from two different volunteers. Cytotoxicity was measured every day
using LDH cell viability assay. The data shown here represent n#3 experiments. One-way
ANOVA was used to measure statistical significance. * represents significance when
compared to control, # represents significance when compared to ALC/APAP.
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significantly reduced the additional toxicity caused by co-treatment of ALC/APAP and
plasma exosomes (Figure 4-3A&B). To further confirm the potential impact of plasma
exosomal CYP2E1 in ALC-induced toxicity, we silenced the cellular expression of
CYP2E1 in HepaRG hepatocytes with CYP2E1 siRNA and then exposed cells with ALC
+ exosomes. As expected, we observed that CYP2E1 siRNA treatment significantly
rescued the cells from ALC-induced toxicity, while it did not reduce/abolish exosomeinduced toxicity (Figure 4-3C).
Effect of human plasma exosomes on U1 monocytic cells
We previously reported that ALC-induced CYP2E1 expression in
monocytic/macrophage cell lines resulted in increased oxidative stress and cytotoxicity
[118]. It is likely that addition of external CYP2E1 load into an in vitro system will
exacerbate CYP2E1-mediated toxicity in U1 cells. Therefore, we treated U1 cells with 50
mM ALC (physiological concentration of ethanol in binge drinking [330]) and 0.5 mM
APAP (sub-toxic physiological concentration [331]) along with plasma exosomes. After
2 days, we observed that plasma exosome treatment caused increased toxicity with both
ALC and APAP co-treatment (Figure 4-4 A&B). This result further suggests that plasma
exosomal CYP2E1 cargo can have significant physiological effects not only in hepatic,
but in extra-hepatic cells as well.
Effect of alcohol on exosomal CYP2E1 derived from mice plasma
To verify our in vitro findings, we isolated exosomes from the plasma of mice
treated with and without alcohol (binge exposure). Although the role of CYP2E1 in
alcohol-induced liver toxicity is well known in alcohol-drinking mice model, the
contribution of plasma exosomes via CYP2E1 in toxicity is unknown. Therefore, we
measured changes in the protein expression of CYP2E1 and two antioxidant enzymes
(AOEs), SOD1 and catalase along with exosomal marker protein CD63 (Figure 4-5A).
Interestingly, the average level of CD63 was reduced in alcohol-treated mice. The most
crucial observation, however, was an increase in the level of CYP2E1 in binge-drinking
mice (Figure 4-5A). The levels of the AOEs, SOD1 and catalase, were also decreased,
suggesting an overall increase in oxidative stress components in the exosomes derived
from ALC-treated mice.
Effect of mouse plasma exosomes on U1 cells upon ethanol treatment
Since we observed increased CYP2E1 and reduced AOE expression in exosomes
derived from ALC-treated mice, we anticipated that this phenomenon will contribute to
enhanced ALC-induced toxicity in the recipient cells. To examine this, we co-treated U1
cells with 50 mM ALC ± exosomes isolated from control or binge-drinking mice. After 4
days of ALC treatment, we observed that exosomes derived from ALC-exposed mice
caused significantly higher toxicity than exosomes from the control group (Figure 4-5B).
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Figure 4-3. Rescue of exosomal CYP2E1 mediated toxicity by selective CYP2E1
inhibitor (DE) and CYP2E1 siRNA.
A-B) HepaRG cells were treated with human plasma exosomes ± ALC/APAP
with/without DE for 2 days. One-way ANOVA was used to measure statistical
significance. * represents significance when compared to control, # compared to
EXO+ETH/APAP. C) HepaRG cells were treated with human plasma exosomes ± ALC
with/without CYP2E1 siRNA. Cytotoxicity was measured using LDH cell viability assay.
The data shown here represent n#3 experiments. One-way ANOVA with Tukey’s
multiple comparison test was used to measure statistical significance. # represents
significance when compared against scramble, $ compared to ALC + scramble, ^
compared to ALC + si2E1.
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Figure 4-4. Effect of plasma exosomal CYP2E1 in U1 cells upon ethanol
treatment.
Plasma exosomes were isolated from healthy human plasma and then treated to U1 cells
+/- ALC/APAP for 2 days. Cytotoxicity was measured using LDH cell viability assay.
The data shown here represent n#3 experiments. One-way ANOVA was used to measure
statistical significance. * represents significance when compared to control, # compared
to ALC/APAP.

Figure 4-5. Effect of alcohol on murine plasma exosomal CYP2E1 and AOEs.
A) Expression of CYP2E1, SOD1, and catalase in plasma exosomes in binge-drinking
mice. B) Effect of exosomes derived from ALC fed mice on ALC-induced toxicity in U1
cells after 4 days. One-way ANOVA was used to measure statistical significance. *
represents significance compared to control and control-exosomes (C-Exo), # represents
significance compared ALC induced exosomes (E-Exo), $ represents significance relative
to ALC and ALC+C-Exo.
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Discussion
CYP2E1, one of the key components of the microsomal ethanol oxidizing system
(MEOS), is mainly involved in metabolism of small molecular xenobiotics [39]. CYP2E1
can activate procarcinogens and other toxic compounds found in cigarette smoke and
various environmental pollutants [332-334]. However, the most clinically relevant role of
CYP2E1 is associated with ALC and APAP metabolism, especially at their higher doses.
Though liver is the primary site where CYP2E1 mediated metabolism exerts its most
damaging effect, extra-hepatic tissues are often affected to a various degree as well [335,
336]. While the hepatic pathway of ALC- and APAP-induced toxicity is well established,
the extra-hepatic mechanism(s) for ALC- and APAP-induced toxicity is not clearly
defined. We recently reported that CYP2E1 is abundantly present in exosomes derived
from healthy human plasma [48]. We also predicted that the majority of the CYP2E1 in
plasma exosomes are derived from hepatic cells, along with some from extra-hepatic
cells. Based on our previous findings, we hypothesized that the metabolically active
plasma exosomal CYP2E1 cargo participates in cellular pathophysiology and contributes
to ALC- and APAP-induced toxicity in hepatic and non-hepatic cells.
In our current study, we observed that plasma exosomes treatment
additively/synergistically increased ALC- and APAP-induced toxicity in HepaRG
hepatocytes and U1 monocytic cells. Further, using CYP2E1 specific inhibitor and
CYP2E1 siRNA, we confirmed the role of CYP2E1 in exosomes induced toxicity.
Besides, we found that alcohol exposure increases packaging of CYP2E1 in exosomes
derived from plasma of mice. We also observed enhanced toxicity when these ALCinduced exosomes were treated to U1 cells, compared to treatment with exosomes
derived from non-drinking mouse plasma. The results suggest that the exosomal cargos,
specifically CYP2E1, may have far-reaching metabolic consequence in ALC- and APAPinduced pathogenesis in hepatic and extra-hepatic cells (Figure 4-6).
Exosomes are released by almost all cell types into their extracellular space or
into biofluids such as plasma [337]. Recent studies on exosomes reveal that they can be
actively involved in intercellular communication with both beneficial and harmful
physiological consequences [325, 338-340]. Exosomes have been suggested as a potential
biomarker in ALC and APAP associated pathologies. Several studies have reported
circulating exosomal miRNAs as potential marker for ALC and other drug induced
inflammatory liver diseases. For example, Momen-Heravi et al., (2015) showed that liver
derived exosomal transfer of miR-122 rendered monocytes more sensitive to
inflammation, which is a key phenomenon in AH pathogenesis [341]. They also showed
that the number of exosomal production was increased and the ethanol concentration in
the human sera was reduced after ALC consumption. Another study demonstrated that
ALC mediated increased EV production and macrophage activation follows CYP2E1dependent pathway [177]. Similar studies have been conducted relating exosomal
pathway and APAP-induced injury. Cho et al., (2018) showed that exosomes obtained
from APAP-induced liver injury caused toxicity in the naïve recipient hepatocytes in a
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Figure 4-6. Schematic representation of the plasma exosomal CYP2E1 mediated
toxicity.
Plasma derived exosomes can carry metabolically active CYP2E1 which may influence
the metabolic pathway of ALC and APAP in hepatic and extra-hepatic cells resulting in
increased cytotoxicity.
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mouse model [342]. Another study suggests that alteration in the hepatocytes derived
exosome levels can act as an early predictor of liver injury in subtoxic APAP exposure
[343]. These studies are shedding new light in the phenomenon of xenobiotics-induced
toxicity and disease pathogenesis.
Plasma exosomes contain not only CYP enzymes but also many other
macromolecules such as miRNAs [344]. Exosomal miRNAs, especially the mir200
family, have been hypothesized as a major target to combat oxidative stress-induced
effects. CYP2E1-mediated increased oxidative stress in hepatocytes upon ALC exposure
is expected to induce mir200s, which are packaged in exosomes, secreted, and circulated
in the plasma [345]. The mir200s promote oxidative stress by disrupting the
SIRT1/FOXO1/eNOS pathway and inhibiting transcription of antioxidant enzymes
(AOEs), especially catalase [346]. A reduced level of AOEs compromises their ability to
neutralize ROS, and thus contributes to enhanced oxidative stress. Dysregulation of mir200s and resultant oxidative stress cause apoptosis and cellular senescence in many cells
[347]. Hence, exosomal mir200s- and CYP2E1-induced oxidative stress would enhance
ALC-induced toxicity additively and/or synergistically. We have observed that plasma
exosomes derived from alcohol drinker subjects contain significant level of mir-200c-3p
compared to healthy subjects (unpublished observation).
Exosomal miRNAs, especially the mir200 family, have been hypothesized as a
major target to combat oxidative stress-induced effects[348]. CYP2E1-mediated
increased oxidative stress in hepatocytes upon ALC exposure is expected to induce
mir200s, which are packaged in exosomes, secreted, and circulated in the plasma[345].
The mir200s promote oxidative stress by disrupting the SIRT1/FOXO1/eNOS pathway
and inhibiting transcription of AOEs, especially catalase[346]. Dysregulation of mir-200s
and resultant oxidative stress cause apoptosis and cellular senescence in many cells[347].
Hence, exosomal mir200s- and CYP2E1-induced oxidative stress would enhance ALCinduced toxicity additively and/or synergistically. We have observed that plasma
exosomes derived from alcohol drinker subjects contain significant level of mir-200c-3p
compared to healthy subjects (unpublished observation).
We observed a somewhat similar phenomenon when plasma exosomes from a
binge-drinking mouse model were characterized for their AOE expression. The
expression of CYP2E1 enzyme was significantly upregulated, while SOD1 and catalase
were downregulated upon alcohol exposure in these mice. When these exosomes were
treated or exposed to recipient U1 monocytic cells, the ALC-induced toxicity was further
exacerbated. The overall increase in oxidative stress elements mediated by CYP2E1 in
the ALC-induced exosomes may have acted as an underlying factor in the increased
toxicity.
Through the findings of this study we suggest that plasma exosomes contribute to
ALC/APAP-induced toxicity, via delivery of CYP2E1 to cells that have high cellular
CYP2E1 (hepatic) as well as low cellular CYP2E1 (monocytic) levels. Upon further
validation, the plasma exosomal CYP2E1 pathway may help to better understand ALC-,
APAP-, and other xenobiotic-induced toxicity, especially in the extra-hepatic tissues.
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Plasma exosomes as “liquid biopsy” has been gaining attention in the drug metabolism
and drug- drug interaction (DDI) arena of drug development [349]. Improvement of
analytical techniques has enabled the quantification of many endogenous components in
human biofluids such as plasma. Hence, plasma exosomal CYP2E1 load, along with
other relevant CYPs, can be taken into consideration while studying DDI and
pharmacokinetic profiling of new and existing drugs. This will not only help
understanding drug-induced pathologies in the hepatic and extra-hepatic tissues but also
in optimizing dosing regimens.
In conclusion, this study demonstrates that both human and murine plasma
exosomal cargo, specifically CYP2E1, play a role in exacerbating ALC- and APAPinduced toxicity in hepatocytes and monocytes. Exosomal transport between cells can be
either beneficial or harmful, and thus a better understanding of the roles of exosomes in
drug abuse/overdose conditions is crucial.
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CHAPTER 5.

CONCLUSION AND FUTURE DIRECTIONS
Conclusion

Despite having many therapeutic properties, the usage of DAS is restricted due to
its own inherent toxicity. Therefore, there was a critical need for replacing DAS with a
safer CYP2E1 inhibitor. In aim 1, we conducted a thorough analysis of the CYP2E1
inhibition kinetics of DAS and seven structural analogs. This study provided several DAS
analogs that showed better inhibition characteristics than DAS. In aim 2, we observed
that at least three DAS analogs- thiophene, allyl methyl sulfide, and diallyl ether
appeared to be less toxic than DAS for the cellular models evaluated in this project.
These compounds were also better than DAS with regard to rescuing ALC- and APAPinduced toxicity as well as reducing viral replication. Overall, the results are very
encouraging in the search for a superior alternative to the widely used DAS as a selective
CYP2E1 inhibitor as a research tool and/or as a possible combination/preventive therapy
in ALC-, APAP-, and other xenobiotic-induced toxicity.
For the second project, we assumed that plasma exosomal CYP2E1 cargo could
play critical role in xenobiotics-induced toxicity. In this project, we demonstrated that
both human and murine plasma derived exosomal cargo, specifically CYP2E1, play a
significant role in exacerbating ALC- and APAP-induced toxicity in hepatocytes and
monocytes. By inhibiting cellular CYP2E1 by DE (one of the newly identified CYP2E1
inhibitors) as well by siRNA, we observed that plasma exosomes can enhance
cytotoxicity by participating in the metabolism of ALC and APAP in both hepatic and
non-hepatic cells.
Future Directions
Upon further analysis, the newly identified analogs may replace DAS as a
research tool or potentially, as a therapeutic regimen for preventing CYP2E1-mediated
xenobiotic- and disease-induced toxicity. The immediate next goal should be evaluating
these analogs in in vivo systems using appropriate animal models to verify our in vitro
findings. Despite its use in research for many years, the pharmacokinetic properties of
DAS are not well characterized. Therefore, evaluation of the pharmacokinetic parameters
of DAS and the new analogs using suitable in vitro and in vivo systems should be
undertaken to better understand the pharmacokinetic/pharmacodynamic relationship of
these compounds. Successful completion of these studies is required for the novel
analogs to be considered as either a dietary supplement or as an adjuvant therapy in
CYP2E1 mediated pathologies.
Since intra- /inter-cellular exosomal transport of biomolecules can be either
beneficial or harmful, a better understanding of the roles of exosomes in drug
abuse/overdose conditions is crucial. Hence, further studies, especially using human
plasma exosomes from alcohol drinkers and acetaminophen abuse/overdose patient, are
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required to explore the full potential of exosomal CYP2E1 cargo and other CYP
enzymes, as biochemical mediators in ALC and APAP metabolism and resulting toxicity.
CYP2E1 in plasma exosomes may translocate to the brain by crossing the BBB and can
contribute to the metabolic pathway of the CNS, an area which requires significant
investigation. Using in vitro and in vivo studies, it is crucial to check the uptake of these
exosomal CYP2E1 cargo into the brain and their probable role in ALC and APAP
metabolism-induced neurodegenerative effects. Moreover, exosomes can be engineered
to carry small molecular pharmaceutical drugs as well as large biomolecules such as
proteins. The newly identified safer DAS analogs can be packaged in exosomes and thus,
can be used for inhibiting CYP2E1 mediated metabolism of ALC and APAP in the brain.
Moreover, exosomes can be manipulated to carry antioxidant enzymes to be delivered to
the CNS which can help alleviate oxidative stress induced neurodegeneration. These are
some exciting therapeutic intervention strategies which require in depth research by using
appropriate in vitro and in vivo model. Additionally, the roles of other prevalent CYP
enzymes in the plasma exosomes needs further attention. CYP3A4 is responsible for
metabolism of ~50% of the pharmaceutical drugs [350]. Hence, it is important to look
into the contribution of plasma exosomal CYP3A4 as well as other drug metabolizing
enzymes in relevant xenobiotic- and diseases-induced pathologies.
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